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Resumo 
 
A presença de produtos farmacêuticos em ecossistemas aquáticos é um problema 
crescente, em particular a classe de drogas psicoativas, cujo consumo tem vindo a 
aumentar devido à crise econômica e outros problemas sociais. Além disto, as 
concentrações destas substâncias no ambiente têm vindo a aumentar, sendo os seus 
efeitos em espécies não alvo ainda desconhecidos. A norflluoxetina é um inibidor 
seletivo da reabsorção de serotonina (SSRI) e é o metabolito ativo da fluoxetina, um 
dos antidepressivos mais consumidos no mundo. A venlafaxina é um inibidor seletivo 
da recaptação de serotonina e de noradrenalina (SNRI). É comercializado sob a 
designação comercial de Effexor e é também um dos antidepressivos mais 
consumidos mundialmente. Estes compostos são duas das drogas mais 
frequentemente detetadas em ambientes aquáticos e o conhecimento dos seus 
efeitos em organismos aquáticos é ainda escasso. Portanto, é necessário 
compreender seu impacto nos organismos não-alvo. Os embriões de teleósteos 
(peixes-zebra) foram utilizados como modelo neste estudo para investigar os efeitos 
dessas substâncias. Foram escolhidos estes embriões devido à sua transparência e 
facilidade de manuseamento que permite monitorizar o desenvolvimento do embrião. 
Este trabalho tem como principais objetivos, compreender a influência das 
exposições individuais, tanto para norfluoxetina e venlafaxina no desenvolvimento 
embrionário do peixe-zebra, e avaliar os efeitos dessas drogas sobre os genes 
envolvidos no modo de ação e metabolização de ambas as substâncias. A 
investigação dos efeitos de um cocktail de ambas as substâncias sobre os níveis 
encontrados em sistemas aquáticos naturais foi realizada. 
Os embriões foram recolhidos uma hora após a fertilização (HPF) e expostos durante 
80 horas a diferentes concentrações de norfluoxetina (0,64, 3.2, 16, 80 e 400ng/L), 
venlafaxina (16, 80, 400, 2000 e 10000ng/L) ou um cocktail de 3.2ng/L norfluoxetina e 
2000ng/L venlafaxina. Nesta gama de concentrações foram incluídos valores 
previamente encontrados em amostras recolhidas em ambiente natural. Durante este 
período, foram feitas observações ás 8, 32 e 80 hpf para registrar o número de 
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embriões mortos e anormalidades do desenvolvimento. A transcrição de mRNA dos 
genes de interesse foi medida por meios de qRT-PCR. Os genes alvo eram recetores 
e transportadores neuro-hormonais (serotonina, dopamina e norepinefrina), 
monoamina oxidase, transportador vesicular de monoaminas, vários recetores 
nucleares, bem como genes envolvidos em processos de desintoxicação e 
antioxidantes. Os resultados mostram que tanto a norfluoxetina como a venlafaxina 
não tiveram influência sobre as taxas de mortalidade, enquanto que o cocktail causou 
mortalidade significativa em todos os pontos de observação (p<0.05), em relação ao 
controlo. Este aumento de mortalidade foi, ainda assim, mais proeminente entre as 0 
e 8 horas pós fertilização. Além disso, a exposição a norfluoxetina, venlafaxina ou um 
cocktail, causou um aumento de anormalidades totais encontrados durante o 
desenvolvimento embrionário. Os embriões expostos ás concentrações mais 
elevadas nos testes foram os mais afetados. Anormalidades na pigmentação, 
coluna/cauda e saco vitelino foram as mais significativas. As anomalias encontradas 
ao nível da pigmentação em todas as condições testadas podem ser utilizadas como 
indicador de exposição. Quanto à expressão de genes, foram encontradas mais 
diferenças significativas em relação ao controle nas exposições a venlafaxina do que 
a norfluoxetina (p <0,05). Para a norfluoxetina um padrão geral de luz de indução da 
expressão génica era visível. A maioria dos genes afetados foram rxrga (3,2 ng / L), 
5-ht2c (80 ng/L), adra2c (0.64ng/L) e Cu/Zn sod (400ng/L). Na venlafaxina, um 
padrão geral de inibição de expressão génica foi detetado. Os genes que sofreram 
maior inibição foram transportadores abc, recetores nucleares rxr e ppar, 5-ht2c, 
drd1b e vmat2. Estes genes possuem uma resposta em forma de U na gama de 
80-2000ng/L, em que a concentração de 400ng/L foi a mais afetada (inibida), o que 
poderá significar que as abordagens tradicionais nos cálculos de risco podem não ser 
as ideais para essa substância. Esses genes exibiram fortes correlações entre si, 
devendo o seu uso como possíveis marcadores de exposição ser estudado em maior 
detalhe. Estes genes mostraram uma forte correlação entre si e têm sido previamente 
associados com alterações no metabolismo dos lípidos e da estimulação de 
dopamina. Em embriões expostos ao cocktail foi testado um conjunto de genes mais 
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pequeno. A seleção foi baseada nos resultados obtidos para os compostos 
individuais. Os resultados mostraram diferenças entre genes neuro-hormonais e de 
metabolização, com inibição e respostas intermediárias maioritárias especialmente 
em relação ás exposições individuais, respetivamente. O padrão de resposta ao 
cocktail foi mais parecido com o da norfluoxetina. 
No geral, os resultados obtidos para esta janela de desenvolvimento parecem 
contradizer a ideia geral de que a norfluoxetina é mais potente do que o composto 
parental. Deve também ser ressalvado que concentrações de venlafaxina na gama 
de 80-2000ng/L estão dentro do intervalo encontrado em meio aquático. Além disso, 
abcb4, a primeira linha de defesa dos peixes foi inibida em concentrações ambientais 
relevantes, que significa que esta substância pode pôr em perigo a sobrevivência do 
organismo. Os resultados do cocktail parecem sugerir uma ação antagonista entre os 
dois fármacos. Contudo, foram também visíveis algumas relações sinergéticas em 
mais pequena escala. 
Em conclusão, a norfluoxetina, venlafaxina e o cocktail tiveram efeitos sobre o 
desenvolvimento embrionário do modelo teleósteo empregado. Sistemas 
neuro-hormonais e vias de desintoxicação foram particularmente afetadas pela 
venlafaxina, mas os efeitos poderão ser suavizados ou potenciados pela 
coocorrência de ambas as drogas. Pesquisas futuras devem concentrar-se em 
esclarecer estas questões, de forma a entender melhor os seus efeitos negativos 
sobre o meio ambiente natural. 
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Abstract 
 
The presence of pharmaceuticals in aquatic ecosystems is a growing problem, in 
particular the class of psychoactive drugs, which consumption has been increasing 
due to the economic downturn and other social problems. Moreover, the 
concentrations of pharmaceuticals is increasing in aquatic ecosystems and the effects 
of these substances for non-target organisms is still unknown. Norflluoxetine is a 
selective serotonin reuptake inhibitor (SSRI) and is the active metabolite of fluoxetine, 
one of the most consumed antidepressants worldwide. Venlafaxine is a serotonin and 
norepinephrine reuptake inhibitor (SNRI). It is marketed under the trade name Effexor 
and is also among the most consumed antidepressants. These compounds are two of 
the drugs most frequently detected in aquatic environments and the knowledge of 
their effects on aquatic organisms is still scarce. In this study a teleost embryo 
(zebrafish) was used as model to investigate effects of these substances. The choice 
was due to its transparency, and easiness to handle, which allows to monitor the 
development of the embryo. The present work had the main objectives of 
understanding the influence of single exposures to both norfluoxetine and venlafaxine 
in the embryonic development of zebrafish, as well as, to evaluate effects of these 
pharmaceuticals in genes implicated in the mode of action and metabolisation of both 
substances. Investigation of the effects of a cocktail of both substances at levels found 
in natural aquatic systems was also carried out. 
Embryos were collected 1-hour post-fertilization (hpf) and exposed for 80 hours to 
different concentrations of norfluoxetine (0.64, 3.2, 16, 80 and 400ng/L), venlafaxine 
(16, 80, 400, 2000 and 10000ng/L) or a cocktail of 3.2ng/L of norfluoxetine and 
2000ng/L of venlafaxine. Those concentrations included values previously found in 
environmental samples. During this period, observations were made at 8, 32 and 
80hpf to register the number of dead embryos and developmental anomalies. mRNA 
transcription of genes of interest was measured by qRT-PCR. The target genes were 
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neurohormonal (serotonin, dopamine and norepinephrine) receptors and transporters, 
monoamine oxidase, vesicular monoamine transporter, several ligand-binding nuclear 
receptors, as well as genes involved in detoxification and antioxidant processes. 
Results show that both norfluoxetine and venlafaxine had no influence in mortality 
rates. For the cocktail was visible a significant induction of mortality in all analysis 
points (p<0.05), relative to the control. However, this increase was prominent between 
0 and 8hpf. On the other hand, exposure to norfluoxetine, venlafaxine and cocktail, 
caused an increase in the total anomalies found during embryonic development, 
although in different stages of the embryonic development. Embryos exposed to 
higher test concentrations were the most affected ones. Anomalies in pigmentation, 
vertebral column/tail and vitelline sac were the most significant. Anomalies in 
pigmentation found in all test conditions can be used as an exposure indicator. 
Concerning gene expression, more significant differences relative to control were 
found for venlafaxine than norfluoxetine (p<0.05). For norfluoxetine a pattern of slight 
gene induction was visible. Most affected genes were rxrga (3.2 ng/L), 5-ht2c (80 
ng/L), adra2c (0.64ng/L) and Cu/Zn sod (400ng/L). For venlafaxine, a general pattern 
of gene inhibition was detected. Most inhibited genes were abc transporters, rxr and 
ppar nuclear receptors, 5-ht2c, drd1b and vmat2. These genes presented a u-shape 
response in the range 80-2000 ng/L, where 400ng/L concentration was the most 
affected (inhibited), meaning that traditional approaches in risk calculations may not 
be the ideal for this substance. These genes showed strong correlations among each 
other and the use of them as exposure indicators should be study in more detail. 
These genes, have been previously associated to disturbances in lipids and 
xenobiotics metabolism and efflux, as well as, dopamine stimulation related to drug 
dependence in the CNS. In cocktail-exposed embryos a smaller pool of genes was 
tested. The selection was based on the results obtained for the single compounds. 
Results showed differences between neurohormonal and metabolisation genes, with 
inhibition and mostly intermediate responses in relation to the single exposures, 
respectively. The cocktail pattern of response resembled more closely that of 
norfluoxetine. 
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Overall, the results obtained for this developmental window counteract the 
general idea that norfluoxetine is more potent than the parental compound. 
Venlafaxine concentrations 80-2000ng/L are within the range found in aquatic 
compartments. Moreover, abcb4, the first line of defence of fish, was significantly 
inhibited at environmentally relevant concentrations meaning that this substance can 
jeopardise organism survival. The cocktail results, suggest an antagonistic action for 
the two substances in some of the tested genes, mainly the ones involved in the 
substance metabolism. However, some synergetic effects also occurred on a smaller 
scale.  
In conclusion, norfluoxetine, venlafaxine and the cocktail had effects on 
embryonic development of the teleost model employed. Neurohormonal systems and 
detoxification pathways were especially affected by venlafaxine, but may be 
potentiated or attenuated by co-occurrence of both drugs, depending on the endpoint 
evaluated. Future research should focus on clarifying this to better understand its 
negative effects on the natural environment. 
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Chapter 1: Introduction and objectives
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1.Introduction 
 
1.1. Pharmaceuticals as environmental pollutants 
 
Contamination of aquatic ecosystems by pharmaceuticals is a problem that has 
been rising continuously in the last decades. Substances in this class of 
pharmaceuticals are nowadays recognized as emerging contaminants of public and 
scientific concern (Evgenidou et al., 2015). Considering current social habits, 
increased life expectancy and population growth on the planet, consumption and 
generation of pharmaceuticals is globally increasing. Cconsequently, detection of 
these substances is becoming more usual and persistent in different sampling 
environments like natural water, drinking water and wastewater (Corcoran et al., 2010; 
Ortiz de García et al., 2014). Hence, there is an increased interest in the study of 
occurrence, fate and impacts of pharmaceutical products on the aquatic environment 
that led to a large number of published papers in recent years (Ortiz de García et al., 
2014; Evgenidou et al., 2015).   
The first studies in this area date back to the 1970s. However, only in the 1990s 
investigation and knowledge about contamination by pharmaceuticals in the aquatic 
environment increased, mainly due to advances reached in analytical methods (Fent 
et al., 2006). Pharmaceuticals are very soluble and occur in small concentrations in 
the aquatic environment. Because of that methods traditionally employed to analyse 
aquatic pollutants were ineffective (Daughton and Ternes, 1999). Only in the 1990s 
the panorama changed and new methods, with higher separatory efficiencies and 
ability to find more polar compounds appeared, allowing scientists to detect 
concentrations in environmental compartments in the order of ng/L and μg/L 
(Daughton and Ternes,1999; Fent et al., 2006; Santos et al., 2010).  
Pharmaceuticals are designed to have a specific mode of action, in order to exert 
their desired therapeutic effect. However, these are also characteristics that make 
them persistent in the environment and, ultimately, cause potential toxicity to fauna 
and flora (Fent et al., 2006). This is even more visible in the aquatic environment. 
Pharmaceuticals are polar and non-volatile. Their distribution is made by aqueous 
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transport, which retains pharmaceuticals in water, making aquatic organisms 
susceptible to these pollutants (Santos et al., 2010). Although risks to wildlife are 
known, existing knowledge in this field is still scarce in important aspects such as 
toxicity of metabolites, conjugates and degradation products of pharmaceuticals 
(Evgenidou et al., 2015). Risks to wildlife exist not only at an acute toxicity level. 
There are also risks of long-term exposure, though these ones remain mostly 
unknown (Ortiz de García et al., 2014; Corcoran et al., 2010). Another problem is that 
pharmaceutical products can raise concern not only as sole compounds per se, but 
also in complex mixtures of different substances (Evgenidou et al., 2015). 
 
1.2 Sources of environmental contamination by pharmaceuticals 
 
Pharmaceutical products are continuously released in the environment, although 
in small quantities (Santos et al., 2010). After being consumed by humans, 
pharmaceuticals pass through liver phase I and II of drug metabolism, where they 
become more water soluble (phase I) and subsequently conjugated and/or excreted 
(phase II). Due to these reactions, pharmaceuticals are excreted by humans in two 
different forms: unchanged or in the form of metabolites (Brown et al., 2015). Hospital 
effluents and direct elimination (e.g. through inadequate sanitary disposal) of unused 
pharmaceuticals in sewage are among the most important sources of contamination 
(Santos et al., 2010) (Figure 1.). 
Effluents are treated in WWTPs (Waste Water Treatment Plants) by three main 
processes of pollutants’ removal, although only two are legally required. In the first 
treatment, the removal of suspended solids occurs. This treatment has a low degree 
of efficiency in the removal of micro pollutants like pharmaceuticals. In the second 
treatment several types of reactions occur, such as: dilution, partition, biotic and 
abiotic transformation (Luo et al., 2014). In this treatment the level of efficiency is 
variable depending on the pharmaceutical in question (Luo et al., 2014). The third 
treatment is optional and is related to health questions to humans or specific purposes 
of the treated water and consists in further removal of some compounds like nitrogen 
or phosphorus (Luo et al., 2014; Guardabassi et al., 2002). After this processing, in 
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some cases, effluent concentrations can be higher than influent ones (Luo et al., 
2014). This can be explained by the presence in influents of some substances, like 
metabolites, that can be transformed back into the parental compound during the 
biological treatment in WWTPs. Pharmaceuticals can also be imprisoned in faecal 
matter and released in the water during biological treatment increasing the overall 
concentration of the substance (Luo et al., 2014). This shows that WWTPs are still not 
designed to treat pharmaceuticals and the existing treatments are not fully efficient in 
the removal of this kind of pollutant. This results in discharges of pharmaceuticals, 
together with treated effluents, in surface and ground water and their consequent 
occurrence in drinking water (Luo et al., 2014; Santos et al., 2010).  
The use of pharmaceuticals is not exclusive of humans. This kind of substances 
is also used in agriculture and aquaculture to treat diseased animals. Such 
pharmaceutical products are excreted in the urine and faeces of animals, entering in 
the environment without any kind of treatment and contaminating the soil, and 
consequently ground water (Santos et al., 2010). Other anthropological activities also 
act as sources of contamination. Industry discharges, sometimes illegally, or the use 
of WWTPs sludge contaminated with pharmaceuticals as fertilizer, are examples of 
these (Santos et al., 2010). 
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Figure 1. Schematic representation of the sources and fate of pharmaceuticals in the environment 
(adapted from Kummerer, 2001) 
 
Nowadays, all classes of pharmaceuticals are detected in the aquatic 
environment. Concentrations found vary according to the class of pharmaceuticals 
and the zone of the globe where sampling is conducted (Fent et al., 2006; Santos et 
al., 2010). Some classes of pharmaceuticals are more consumed than others and that 
can contribute to a higher detection of some classes in the environment. This 
relationship between the use and detection of pharmaceuticals, however, is not 
always correct (Fent et al., 2006). The presence of a pharmaceutical in the 
environment is also connected to the physico-chemical properties of the 
pharmaceutical that influence the persistence and durability of the substance in the 
water. Also the percentage of removal in WWTPs is linked to different levels of 
occurrence of pharmaceuticals in the water given that, like previously mentioned, the 
quantities of removal differ greatly from substance to substance; this can explain in 
part differences in the quantities detected in the aquatic environment (Santos et al., 
2010; Luo et al., 2014)   
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1.3 The case of antidepressants  
 
With the human population exposed to increased stress as a result of the current 
economic and social context, antidepressants’ consumption has risen on a large scale 
around the world. Indeed, this class of drugs is one of the most detected in the 
environment (Santos et al., 2010; OECD, 2014). In Europe, recent data show that 
consumption of antidepressants has risen considerably since 2000 (OECD, 2014). 
Portugal, in particular, is one of the European Union countries where antidepressant 
consumption was higher in 2012 (Figure 2.) (OECD, 2014). This increasing 
consumption is also linked with the massive appearance of the selective serotonin 
reuptake inhibitors (SSRI) type of antidepressants in the market and most recently 
with the appearance of serotonin–norepinephrine reuptake inhibitors (SNRI) (Gusmão 
et al., 2013; Melnyk-Lamont et al., 2014).  
 
Figure 2. Evolution of consumption of antidepressants between 2000 and 2012 in Europe (adapted from 
Health at a Glance: Europe 2014, OECD) 
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1.3.1 Selective Serotonine Reuptake Inhibitors (SSRI): fluoxetine and 
norfluoxetine 
 
SSRI are a class of antidepressants that comprise six different main compounds: 
fluoxetine, sertraline, escitalopram, paroxetine, fluvoxamine and citalopram (Patel et 
al., 2015). In this work we are going to focus in fluoxetine metabolite, norfluoxetine.  
Like previously mentioned fluoxetine is an antidepressant of the SSRI class. Its 
main indications are for use in moderate to severe depression, obsessive-compulsive 
disorder, food and panic disturbances and anxiety (Dulawa et al., 2004). It is used as 
fluoxetine hydrochloride, commonly under the trade name Prozac, in two different 
forms: oral solution and a capsule formulation. It is one of the most used and 
prescribed antidepressants worldwide (Mennigen et al., 2011; Winder et al., 2012). 
The marketed drug, is a racemic mixture of two different enantiomers, r-fluoxetine and 
s-fluoxetine. The two enantiomers have similar potency (Baumann et al., 2002). The 
bioavailability of the two different marketed forms is almost similar (De Vane., 1999). 
The overall bioavaibility of fluoxetine, however, tends to be low due to the presystemic 
metabolism of vertebrates (DeVane, 1999). Fluoxetine is also stable in water and has 
frequently been detected in aquatic environments, in concentrations in the order of 
ng/L to ug/L (Barry, 2013). 
The mode of action of SSRI antidepressants involves the inhibition by presynaptic 
receptors of serotonin (5-hidroxitroptamine, 5-HT) reuptake. This increases the overall 
concentration of active serotonin in the synaptic cleft, potentiating its effect (Mennigen 
et al., 2011) (Figure 3.). Serotonin is a neurotransmitter involved in neural and 
hormonal mechanisms participating in the regulation of endocrine regulatory functions. 
Thus, an alteration in serotonin levels can cause changes in various physiological 
processes and the behaviour of an organism (Fent et al., 2006). In this SSRI 
mechanism, in addition to the 5-HT receptors, there are other role players like 
monoamine oxidase (MAO) or vesicular monoamine transporter (VMAT). MAO is a 
monoamine responsible for oxidative deamination of a great number of amines, 
where serotonin is included, independently of its endogenous or exogenous origin 
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(Sallinen et al., 2009). In mammalians two different MAO isoforms are known: MAO A 
and MAO B, while in zebrafish there is only one MAO form. In this fish species, MAO 
presents high affinity to 5-HT and studies suggest that MAO has a major role in 5-HT 
metabolism in adult individuals (Anichtchick et al., 2006). VMAT is a transport protein 
whose function is the uptake of different monoamines, serotonin included, into storage 
vesicles and subsequent release in the central nervous system (CNS). In humans, 
two different kinds of VMATs are known, with different distribution in the tissues: 
VMAT1 and VMAT2. VMAT 1 is mostly present in neuroendocrine cells, while VMAT2 
is mainly expressed in the CNS (Wimalasena, 2011). Although different, VMAT1 and 
VMAT2 have similar binding affinity to serotonin (Wimalasena, 2011). Different studies 
showed that VMAT2 is related with several neurological disorders and stress 
response, like Parkinson’s disease where VMAT2 is used as a diagnostic tool 
(Tillinger et al., 2010; Wimalasena, 2011) 
 
 
Figure 3. SSRI mechanism of action (adapted from: Kreke and Dietrich, 2008) 
 
5-HT receptors have been found in vertebrates and invertebrates. They are 
considered as very conserved from an evolutionary point of view (Kreke and Dietrich., 
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2008). However, their specific role at the physiological level and their mode of action 
is still unknown in many species, making difficult to evaluate the impact of 
environmental exposure to SSRI, particularly in aquatic ecosystems (Kreke and 
Dietrich, 2008; Connors et al., 2014). As SSRI, fluoxetine acts on neural receptors 
leading to alterations in the level of serotonin in the synaptic cleft. Fluoxetine may also 
interact with dopaminergic and adrenergic systems (Kreke and Dietrich, 2008). 
Previous studies on aquatic organisms, particularly in zebrafish, demonstrated that 
serotonin (Schultz et al., 2011) and dopamine (Fontaine et al., 2013) are involved in 
embryonic development, while adrenergic receptors are also responsible for the 
pigmentation in embryos and adults (Xu and Xie, 2011). 5-HT receptors in aquatic 
organisms were found in different parts of the brain and at very early stages of embryo 
development (Kreke and Dietrich, 2008). In fact, in zebrafish, the development of the 
serotonergic system occurs between 1 and 4dpf (days post fertilization). This system 
has two different pathways: the first one occurs between 1 and 2dpf with separate 
populations of serotonergic neurons with growth cones in the spinal cord; the second 
one occurs between 3 and 4dpf with the development of the raphespinal projection 
(Airhart et al., 2012). Furthermore, there is evidence that serotonin and 5-HT 
receptors are also involved in reproduction, immune system and behaviour (Kreke 
and Dietrich, 2008). That said, it is likely that exposure of aquatic vertebrates to SSRIs 
such as fluoxetine, induces changes in the development and behaviour of these 
animals. This is confirmed by several studies that have linked exposure to fluoxetine 
in fish with the disruption of endocrine functions involved in various physiological 
processes at the level of reproduction, growth, stress, immune system and behaviour 
(Mennigen et al., 2011). 
Beyond the parental compound, fluoxetine, its main metabolite norfluoxetine 
(Figure 4.) can also be a possible source of problems to aquatic organisms, since it 
has been discovered in fish tissues and different environmental water samples in the 
order of ng/g and ng/L, respectively (Brooks et al., 2005; Santos et al., 2010). 
Norfluoxetine is considered an SSRI and its use as antidepressant was investigated, 
but the development of the drug was never completed and consequently it did not 
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come to the global market (PubChem, 2015). Like the main compound, norfluoxetine 
presents two different enantiomers, r-norfluoxetine and s-norfluoxetine, but contrary to 
fluoxetine, norfluoxetine enantiomers have different potency, being s-norfluoxetine 
20-fold more potent than r-norfluoxetine (Stanley et al., 2007). In this study was used 
norfluoxetine in solid crystals containing a mixture of both enantiomers. After the 
consumption of fluoxetine by humans, the compound is metabolised in the liver, giving 
rise to norfluoxetine by demethylation reactions (Fong et al., 2008). The 
n-demethylation of r- and s-fluoxetine into its metabolites r- and s-norfluoxetine is 
catalysed by different types of genes from the Cyp (Cytochrome P450) family, in 
humans (Ring et al., 2001). Different Cyp genes are involved in the n-demethylation of 
the two different enantiomers of fluoxetine. Genes involved in the formation of 
r-norfluoxetine are the following: Cyp2D6, Cyp2C9, Cyp2C19, Cyp3A4 and Cyp3A5. 
Among these, Cyp2D6 and Cyp2C9 are the ones with major role in this process. In 
the case of the formation of s-norfluoxetine, Cyps involved are the following ones: 
Cyp2D6, Cyp2C19, Cyp3A4 and Cyp3A5, with Cyp2D6 playing a major role in the 
process (Ring et al., 2001; Margolis et al., 2000). 
Although r- and s-fluoxetine are similar in terms of potency, s-fluoxetine presents a 
higher potential to inhibit Cyp2D6. Studies showed that s-fluoxetine is six times more 
potent at inhibiting Cyp2D6 than r-fluoxetine (Stevens and Wrighton, 1993). Data 
obtained from patients, also showed that s-norfluoxetine concentrations in plasma 
were the double of the r-norfluoxetine ones, but the ratio between them could vary 
from 1.5 to 3 (Potts and Parli, 1992; Torok-Both et al., 1992). Moreover, only a small 
percentage (20 to 30%) of fluoxetine remains unchanged in the urine; the remaining 
percentage is a mixture of different metabolites where norfluoxetine is the most active 
one (Fong et al., 2008). Another difference between fluoxetine and norfluoxetine, lies 
in the half-life time, which is higher for norfluoxetine (Brooks, 2014). Studies have also 
shown that norfluoxetine is more potent than fluoxetine (Hiemke and Hartter., 2000). 
However, only a sparse quantity of studies is available regarding the effects of 
norfluoxetine in aquatic organisms. The first published study in this area dates back to 
2008 and showed that norfluoxetine induces spawning and parturition in bivalves 
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(Fong et al., 2008).  
 
 
Figure 4. Comparison between fluoxetine and norfluoxetine 2D structures (source: PubChem) 
 
 
1.3.2 Serotonin–norepinephrine reuptake inhibitors (SNRI): venlafaxine 
 
SNRI are a class of antidepressants that comprises six different main compounds: 
venlafaxine, desvenlafaxine, duloxetine, milnacipran, levomilnacipran and 
sibutramine (FDA, 2016; Sansone and Sansone., 2014). In this work we are going to 
focus in venlafaxine (Figure 5.).  
 
Figure 5. Venlafaxine 2D structure (source: PubChem) 
 
Like previously mentioned venlafaxine is an antidepressant of the SNRI class. Its 
main indications are for use in the treatment of major depressive disorders, 
generalised anxiety disorders, chronic pain syndromes and social phobia (Gutierrez et 
Fluoxetine Norfluoxetine 
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al., 2003; Sansone and Sansone, 2014). It is used as venlafaxine hydrochloride under 
the trade name Effexor®, in two different forms: immediate release and extended 
release. It is one of the most prescribed antidepressants in the last years (Sansone 
and Sansone, 2014; Melnyk-Lamont et al., 2014). Those two forms are very similar. 
Their main differences are the half-life time (14 hours for extended release and 5 
hours to immediate release), dose per day (twice a day for immediate release and 
once a day to extended release) (Olver et al., 2004; Sansone and Sansone, 2014). 
The extended release form was found to cause less nausea and dizziness. 
Venlafaxine has been detected in the aquatic environment with concentrations 
ranging from few ng/L to 2ug/L in wastewater effluents (Schultz et al., 2010; Gonzalez 
Alonso et al., 2010).  
Both serotonin and norepinephrine are neurotransmitters involved in neural and 
hormonal mechanisms participating in the regulation of endocrine regulatory functions. 
Thus, an alteration in serotonin and norepinephrine levels can cause changes in the 
behaviour of an organism (Fent et al., 2006; Melnyk-Lamont et al., 2014). 
The mechanism of action of SNRIs is similar to that of SSRIs. The main 
difference is that SNRIs, besides the inhibition of presynaptic receptors of serotonin 
reuptake, also inhibit the presynaptic receptors of norepinephrine reuptake (Figure 6.). 
This leads to an increase in the overall concentration of serotonin and norepinephrine 
in the synaptic cleft, potentiating their action (Gutierrez et al., 2003; Mennigen et al., 
2011). 
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Figure 6. SNRIs mechanism of action (from CNS Forum) 
 
Norepinephrine pathways are also very conserved in fish (Kreke and Dietrich, 
2008), however their specific role on the physiology of non-target organisms, like fish, 
are still unknown (Kreke and Dietrich, 2008; Melnyk-Lamont et al., 2014). However, 
these monoaminergic pathways are linked to different kinds of behaviours like feeding, 
locomotion and aggression (Kreke and Dietrich, 2008). In mammals’ venlafaxine 
shows different grades of inhibition depending on the concentration. At lower doses, 
venlafaxine acts as an SSRI, inhibiting only the serotonin reuptake, while at higher 
doses it inhibits both serotonin and norepinephrine (Redrobe et al., 1998). This can be 
explained by the higher affinity of venlafaxine to serotonin receptors than to 
norepinephrine receptors (Montgomery, 2008). Although low, venlafaxine has also 
affinity to dopamine and at high doses may have effects in the reuptake of dopamine 
(Sansone and Sansone, 2014). Like the 5-HT receptors, noradrenergic ones are also 
present in different parts of the brain and at very early stages of embryonic 
development (Kastenhuber et al., 2010). In fact, the first zebrafish adrenergic neurons 
appear after 24hpf, and the overall adrenergic system is complete at 5dpf exhibiting 
high similarity to the system described in adults (Kastenhuber et al., 2010). Since 
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venlafaxine is a SNRI acting in neural receptors, which lead to alterations in the levels 
of serotonin, norepinephrine and even dopamine in the synaptic cleft, it can lead to 
significant alterations in several physiological functions of the organisms (Redrobe et 
al., 1998). In fact, several studies regarding the possible effects of venlafaxine in fish, 
showed that this pharmaceutical may cause alterations in reproduction and behaviour 
(Galus et al., 2013; Schultz et al., 2011). Moreover, alterations in the adrenergic 
system, one of this SNRI targets, can alter pigmentation of zebrafish embryos and 
adults (Xu and Xie, 2011; Ruuskanen et al., 2005); gene expression of neural 
development and regulation (Thomas et al., 2012) and may also block 
epinephrine-induced glucose production affecting the stress response of fish exposed 
to venlafaxine (Ings et al., 2012).  
 
1.4 Biotransformation of xenobiotics (pharmaceuticals) by the organism 
 
The body has several detoxification mechanisms to deal with the presence of 
toxic substances, which eliminates them substances either in their original state or in 
the form of metabolites. Among these mechanisms are biotransformation enzymes of 
phase I and phase II, transport proteins from phase 0 and phase III, and antioxidant 
enzymes. Cytochrome P4501A (CYP1A) and cytochrome P4503A (CYP3A) are main 
phase I enzymes. Glutathione S-transferase (GST) is a major phase II enzyme. 
Membrane proteins of phase 0 and III are ABC transporters (ATP-binding cassette), 
while some main antioxidant enzymes are catalase (CAT) and superoxide dismutase 
(SOD). 
To realize the regulation of genes encoding enzymes of phase I and II, and its 
carriers, it is essential to understand the signalling mechanisms that involve these 
genes and the nuclear receptors (NRs) involved (Wang and Lecluyse, 2003). 
Receptors involved in detoxification mechanisms are already known in mammals. 
Among these receptors are: pregnane X receptor (PXR), peroxisome proliferator 
activated receptors (PPARs) and retinoid X receptors (RXR) (Xu et al., 2005). PXR 
among other functions is known to regulate the expression of CYP3A gene, a main 
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player in phase I biotransformation in humans and rodents (Lehmann et al., 1998). 
PPARs include 3 subtypes (PPARα, PPARβ and PPAR gamma), which have been 
described in several vertebrates, including fish (Ibabe et al., 2005). These receptors 
can induce at least one type of CYP's (Zhao et al., 2006). RXR comprise a family of 
three elements: RXRα, RXRβ and RXRλ. These receptors can form heterodimers with 
other nuclear receptors facilitating the activation and specific binding of all nuclear 
receptors known to date (Wang and Lecluyse, 2003). They can also form 
heterodimers with retinoic acid receptors (RARs) acting at the level of gene promoters, 
modulating its transcription rate (Dollé, 2009). Another important receptor is the Aryl 
Hydrocarbon Receptor (Ahr) that recognizes various structures such as aromatic 
compounds (Hankinson, 1995). Correlations between Ahr and expression of genes 
involved in detoxification (CYP1 and phase II enzymes) in mammals (Nebert et al., 
2004; Rushmore and Kong, 2002) were previously described. In fish, in particular 
zebrafish, the possibility of such interactions, especially in terms of CYP's was 
recently described (Kubota et al., 2015). 
Members of the superfamily ABC (ATP-binding cassette) in aquatic species are 
part of the mechanism denominated MXR (multixenobiotic resistance) (Kurelec, 1992) 
and are considered the first line of defence against toxic substances and its 
metabolites at the cellular level (Bard, 2000). In mammals, ABC proteins are divided 
into different families which include ABCB (P-glycoprotein), multidrug resistance 
associated protein (MRP's) ABCC and breast cancer resistance-associated protein 
(BCRP) ABCG2. All these have shown xenobiotic transport capacity and, 
consequently, have ecotoxicological relevance (Epel et al., 2008). In zebrafish the 
functional P-glycoprotein is ABCB4, performing the same functions as the ABCB1 in 
mammals (Fisher et al., 2013), which is the efflux of unmodified compounds from the 
cells (phase 0) (Figure 7.). However, this first mechanism of defence is sometimes 
overpast by high doses of xenobiotics, that accumulate in the cell (Bard, 2000). In 
those cases, the organism has to apply to other mechanisms of defence. In a second 
defence line, metabolisation or biotransformation of compounds occurs. This can be 
defined as a catalytic/enzymatic conversion of a xenobiotic into a more hydrophilic 
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compound that can be more easily excreted than the parent compound (Van der Oost 
et al., 2003). Biotransformation occurs over two stages; stage I leads to several 
non-synthetic modification reactions including oxidation, reduction or hydrolysis (via 
Cytochrome P450) converting the parent compound into a metabolite. In phase II, the 
metabolite resulting from stage I, can be combined with an endogenous compound 
such as glutathione (Xu et al., 2005). In a third phase (phase III), transport proteins, 
such as ABCC and ABCG, efflux metabolites resulting from phase I and II 
biotransformation (Bard, 2000). Recent works show correlations between the 
expression of ABC transporters and phase I and II enzymes, in fish exposed to 
xenobiotics (Costa et al., 2012).  
 
Figure 7. Schematic representation of the different xenobiotic metabolisation phases 
 
Many compounds can cause oxidative stress (Van der Oost et al., 2003). 
Oxidative stress is defined as damage caused to cellular macromolecules by reactive 
oxygen species (ROS) which can lead to cell death (Van der Oost et al, 2003). 
However, there are mechanisms to combat oxidative stress; namely antioxidant 
enzymes such as catalase (CAT), or superoxide dismutase (SOD) which transform 
ROS into non-reactive molecules (Van der Oost et al., 2003). 
In toxicology and ecotoxicology, in vivo assays are the main tools used to obtain 
crucial data about the effects of a wide range of toxicants in living organisms. This 
information is crucial for ecological risk assessment, allowing decision-makers to 
apply different regulatory strategies for those toxicants (Ankley et al., 2010). However, 
17 
 
this method has low efficiency, extensive animal use, high costs and is time 
consuming; it is thus against the current demands for higher efficiency and less 
animal use (Ankley et al., 2010; Volz et al., 2011). To respond to such demands, in 
recent years, new developments in bioinformatics, measurement technologies and 
toxicological knowledge at the molecular level were reached and new types of assays 
start to be proposed like in silico and in vitro screening (Ankley et al., 2010; Volz et al., 
2011). In order to conciliate the most recent tools available in predictive testing with 
knowledge at the molecular level and the necessity of create new strategies to 
ecological risk assessment, Ankley et al., (2010) proposed the Adverse Outcome 
Pathways (AOP’s) as model.   
An AOP is a conceptual framework that links an initial molecular event of 
interaction between a toxicant and a biomolecule to an adverse outcome at a higher 
organisation level that is relevant to ecological risk assessment (Ankley et al., 2010; 
Kramer et al., 2011). This means that AOP’s take into account a myriad of events that 
occur through several levels of biological organisation (Figure 8.) (Ankley et al., 2010). 
The different types of relationships between the diverse levels of biological 
organisation, and the information supporting those relationships, can be obtained 
from in vivo, in vitro or in silico assays (Ankley et al., 2010). This framework and the 
different linkages that it addresses makes it a very important tool to predictive tactics 
in toxicology and environmental risk assessment (Ankley et al., 2010; Kramer et al., 
2011). Nowadays, AOP’s are widely used in different study subjects, since human 
health, interactions between chemicals and algae, early development in fish and 
obviously risk assessment evaluations (Bal-Price et al., 2016; Vogs and Altenburger, 
2016; Volz et al., 2011; Kramer et al., 2011). 
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Figure 8. AOP sequence of biological organization levels  
 
 
1.5 Test model: zebrafish (Danio rerio) 
 
In this study, the used test model was zebrafish (Danio rerio) (Figure 9). Zebrafish 
is a small freshwater fish that belongs to the family Cyprinidae and has origin in the 
North of India, mainly in the Ganges and Brahmaputra river basins (Spence et al., 
2008; Avdesh et al., 2012; Parichy, 2015). In the lastest years, it has been widely used 
as a vertebrate model in scientific studies in biomedical and environmental sciences 
(Parichy, 2015). Males and females are easily differentiable, mainly before spawning, 
given that females present a more curled belly shape, due to the eggs carried, while 
males have straight shape (Lammer et al., 2009). Another difference between males 
and females is the anal fin that tends to be bigger and yellow in males (Spence et al., 
2008). 
 
 
Figure 9. Zebrafish (Danio rerio) specimen 
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Zebrafish has a range of characteristics that makes this species a widely used 
vertebrate model. It is easy to obtain, maintain and reproduce in laboratory 
environment with low costs (Avdesh et al., 2012); it has high fecundity allowing to 
obtain a large quantity of eggs per spawn (Spencer et al., 2008); eggs have a 
considerable size (0.7mm diameter), are non-adhesive and transparent, which allows 
the monitoring of embryonic development (Kimmel et al., 1995; Spence et al., 2008; 
Soares et al., 2009); embryonic development is fast, approximately 72 hours, 
enabling faster researcher and diagnosis results (Kimmel et al., 1995). Adding to this, 
the zebrafish genome is completely sequenced and publicly available at the National 
Centre for Biotechnology Information (NCBI) Zebrafish Genome Page. These 
characteristics make zebrafish a first choice in different fields such as genetics, 
pharmacology and behaviour (Avdesh et al., 2012). This species is also considered a 
good model for toxicological and ecotoxicological studies since they show clear dose 
responses to different toxics and allow the evaluation of different sets of endpoints. 
Guidelines from OECD are already available for toxicological tests in different phases 
of zebrafish development (Zhang et al., 2003). The embryonic and larval stages are 
the most sensitive and exposure to xenobiotics in these phases may have adverse 
effects on animal development, with consequences at the population level. The 
formation of zebrafish brain starts at 9 hpf (Kimmel et al., 1995). Knowing that 
norfluoxetine and venlafaxine are active in neuronal receptors that start to be put in 
place during very early developmental stages (first two days after fertilization), makes 
this species a good model for studying their mode of action and potential toxic effects 
towards young teleost fish. 
 
 
1.6 Objectives 
 
As previously mentioned, generation and consumption of antidepressants is 
increasing all over the world and this tendency should continue in the near future. 
Consequently, increased discharge of these pharmaceutical products into the 
environment is expected. Consequences for non-target organisms, resulting from 
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those discharges are still little known and should therefore continue to receive 
attention from the scientific community. Research should focus particularly in 
evaluating effects of exposure to single substances and their by-products, as well as 
mixtures of pharmaceutical products, fields where existing gaps in knowledge are 
bigger (Corcoran et al., 2010; Evgenidou et al., 2015).   
The present work, therefore, had the main objectives of understanding the 
influence of single exposures to both norfluoxetine and venlafaxine in the embryonic 
development of zebrafish, as well as, to evaluate effects of these pharmaceuticals in 
genes implicated in the mode of action and metabolisation of both substances. 
Investigation of the effects of a cocktail of both substances at levels found in natural 
aquatic systems was also carried out. The work developed was based on the zebrafish 
embryotoxicity assay with exposures to the selected substances and their mixture. 
Survival and hallmark developmental endpoints, including gross anomalies, were 
recorded throughout the exposures. At the end of assays, embryos were collected and 
used to evaluate the expression of 38 genes involved in neurohormonal and 
detoxification processes selected according to available knowledge on mode of action 
of these substances in other vertebrates. 
This research adds to the knowledge base about the responses of teleost 
embryos to SSRI or/and SNRI exposure. Moreover, it provides information and cues 
to develop early diagnosis of exposure to these environmental contaminants, as well 
as empirical data useful for risk calculations. 
After this general introduction, chapter 2 presents the materials and methods 
employed in the research presented herein. Chapter 3 is dedicated to the presentation 
of the results obtained for norfluoxetine and venlafaxine evaluations, respectively, as 
well as the responses elicited to exposure to the cocktail tested. The general 
discussion of the results obtained is presented in Chapter 4. Finally, Chapter 5 regards 
the conclusions and future perspectives of the research developed, and Chapter 6 
presents the list of references supporting the work. 
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2. Material and methods  
2.1 Used pharmaceuticals 
In this study, two pharmaceuticals were used: norfluoxetine (15900) from Cayman 
Chemical Company® and venlafaxine from the European Pharmacopeia Reference 
Standard®. 
 
2.2 Zebrafish maintenance and reproduction 
Zebrafish (Danio rerio) specimens used in this study, were born and maintained in 
CIIMAR, Porto, Portugal, certified facilities for aquatic organisms. Breeders were 
maintained in 70L tanks with continuous aerification and water circulation at 27 ± 1ºC, 
photoperiod was 12 hours’ light and another 12 hours’ obscurity, and the animals were 
fed twice a day with proper fish food (Tetramin®) and with artemia once a day. 
Males and females were placed in a maternity in a 1:2 ratio (female:male) for 
reproduction. The maternity was placed inside a 30L tank for 12 hours, for 
acclimatisation, and had a net bottom covered with glass marbles to mimic natural 
conditions.   
 
2.3 Zebrafish embryo toxicity test 
 
After reproduction, in the beginning of the light period (at dawn), embryos (0-1 
hours post fertilisation, hpf) were collected, washed and counted. The assays were 
carried out in 24 well plates. Ten embryos were placed in each well in a final volume of 
2ml. Embryos were exposed to different norfluoxetine (0.64, 3.2, 16, 80 and 400 ng/L) 
and venlafaxine (16, 80, 400, 2000 and 10000 ng/L) concentrations during 80 hours. 
In cocktail assays a mixture of 2000ng/L of venlafaxine and 3.2ng/L of norfluoxetine 
was tested. Concentrations ≤3.2ng/L for norfluoxetine, ≤2000ng/L for venlafaxine and 
the ones used in the cocktail are environmentally relevant, which means that these 
concentrations are found in the ecosystems. These assays also included single 
treatments of norfluoxetine and venlafaxine at the concentrations in the mixture for 
comparative purposes and better data interpretation. Solutions were prepared from a 
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stock solution of each test substance diluted in ultrapure water, followed by a dilution 
series. A control group only containing ultrapure water was also included in each 
assay. In the day before the each assay the microplate wells were filled with the 
correspondent treatment volume, in order to avoid adsorption by the testing plates. 
The culture medium was renewed every day during the assay to avoid the growing of 
microscopical organisms that could affect the embryos and/or cause degradation of 
the test substances. Three assays, with two replicates each, were conducted for each 
test substance and the cocktail, in a total of 18 plates (6 per substance/mixture), to 
obtain enough biological material for gene expression determinations. At the end of 
the exposures (80hpf) embryos were collected and preserved in RNAlater for further 
processing and gene expression analysis. 
In this study, three specific time points were selected to evaluate normal 
progression of embryological development, monitoring main embryonic 
developmental stages. At 8hpf one can observe the 75% epiboly stage where the 
embryo general plan is evident, and abnormal tissue masses or developmental delay 
can be checked. At 32hpf embryo segmentation is visible, as well as heartbeats, 
spontaneous movements and some pigmentation; embryo anomalies can be easily 
detected by following these hallmarks. At 72hpf embryos typically hatch. However, in 
some cases, hatching can be delayed taking more time until occurrence (Kimmel et al, 
1995). Because of this, embryos or ecloded larvae were observed at 80hpf to detect 
possible hatching delays and other morphological anomalies. Table I presents the list 
of endpoints recorded in each developmental stage. 
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Table 1. Parameters analysed at different observation points. 
 
 
 2.4 RNA extraction and cDNA synthesis 
 
RNA was extracted from organisms exposed after 80 hours of exposure to 
norfluoxetine and venlafaxine, or their cocktail, using Illustra RNAspin Mini RNA 
Isolation kit (GE Healthcare), according to the manufacturer protocol. RNA quality was 
verified by electrophoresis on an agarose gel with analysis of the 18s and 28s bands 
and by measuring the optical density ratio at λ260/280nm. RNA was quantified using 
a micro-volume (2 µL) quantification method, using Take3 micro-volume plates in a 
BioTek microplate spectrophotometer. Then, 1µg of total RNA was subjected to 
digestion of genomic DNA using deoxyribonuclease I Amplification Grade (Invitrogen) 
and cDNA synthesis was subsequently performed using iScript cDNA Synthesis Kit 
(Biorad) following the manufacturer's protocol. 
 
2.5 Primers design, PCR (polymerase chain reaction) and cloning  
 
Table II indicates the genes which activity was assessed in the exposed zebrafish 
larvae. These were dopamine, serotonin and noradrenaline receptors, the vesicular 
monoamine transporter and the monoamine oxidase gene, serotonin, dopamine and 
norepinephrine transporters, several nuclear receptors, ABC transporters, 
biotransformation and antioxidant enzymes. Reference genes assessed are also 
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indicated in Table II and were an elongation factor, the widely employed actin β1 and a 
ribosomal protein. Pairs of primers (forward and reverse) for the genes of interest 
(Appendix A1) are based on gene sequences available in GenBank and were 
designed in Primer 3 Plus program.  
 
Table 2. Assessed genes and their function in the organism 
Assessed gene Function in the organism 
serta Serotonin transporter 
5-ht2c Serotonin receptor 
5-htt1aa Serotonin receptor 
dat Dopamine transporter 
drd1b Dopamine receptor 
drd2b Dopamine receptor 
net Norepinephrine transporter 
adra2a Norepinephrine receptor 
adra2b Norepinephrine receptor 
adra2c Norepinephrine receptor 
vmat2 Vesicular monoamine transporter 
mao Monoamine oxidase 
pxr Nuclear receptor 
ahr2 Nuclear receptor 
raraa Nuclear receptor 
rarab Nuclear receptor 
rarga Nuclear receptor 
rxraa Nuclear receptor 
rxrab Nuclear receptor 
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Table 2. Assessed genes and their function in the organism 
Assessed gene Function in the organism 
rxrbb Nuclear receptor 
rxrga Nuclear receptor 
rxrgb Nuclear receptor 
pparα Nuclear receptor 
pparβ Nuclear receptor 
pparγ Nuclear receptor 
abcb4 ABC transporter 
abcc2 ABC transporter 
abcc1 ABC transporter 
abcg2a ABC transporter 
Cyp1a1 Phase I biotransformation enzyme 
Cyp3a65 Phase I biotransformation enzyme 
gstπ Phase I biotransformation enzyme 
Cu/Zn sod Antioxidant enzyme 
cat Antioxidant enzyme 
ef1 Reference gene 
actb1 Reference gene 
rpl8 Reference gene 
 
 To confirm the identity of the sequences, PCR (polymerase chain reaction) was 
performed in a Biometra thermocycler with a mixture of 2μL cDNA (cDNA obtained 
from pools of about 40 zebrafish larvae with 80hpf). PCR reaction was performed with 
the following components, volumes and final concentrations, in a final volume of 20µL 
per reaction: 4µL of 5x buffer, 2µL MgCl2 (2.5mM), 1µL of forward primer (1uM) 1µL of 
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reverse primer (1µM), 0.4 µL of DNTP's (0.2 mM), 9.5µL water, 0.1µL of 
TaqPolimerase (Promega) (2.5U) and 2µL of cDNA template. In the thermocycler, the 
reaction was carried out under the following conditions: 2 minutes of denaturation at 
94ºC; 40 cycles of denaturation for 30 seconds, 30 seconds of annealing or 
hybridization at 51ºC, 54ºC, 55 ºC (51ºC for VMAT, 55ºC for receptor of serotonin 
5-HT2c and dopamine drd1b; 54ºC for the remaining genes), 30 seconds of 
polymerisation at 72 ºC and 10 minutes at 72 ºC for a final elongation. The size of the 
bands was evaluated on a 2% agarose gel buffered with 1µL of TAE 1x Gel Red and 
visualized under UV light. Bands of the expected size were excised from the gel and 
purified using the illustra GFX PCR DNA and Tm Gel Band Purification Kit (GE 
Healthcare). Cloning and identification of sequence identity was made according to 
the protocol described by Costa et al. 2013. The fragments were inserted into the 
vector pGEM (pGEM(R) - T Easy Vector Systems - Promega) and introduced into E. 
coli using New Blue Competent Cells (Novagen). Colonies of interest were selected 
(white ones) and developed on solid medium for 10 hours (35 g/L of LB Broth, 
ampicillin 0.1 mg/ml, IPTG 0.1mM and X-gal 100mM) at 37ºC. Plasmids were isolated 
from 5mL of culture medium and incubated overnight with 5µL ampicillin at 37ºC, with 
constant stirring. For subsequent DNA extraction the Wizard Kit Plus SV Minipreps 
DNA Purification System (Promega) was used, according to the manufacturer 
instructions. PCR products were sequenced by Stabvida (Portugal) and the identity of 
the sequences was verified with the Alignment Basic Local Search Tool (Blast) at the 
National Centre for Biotechnology Information (NCBI) (http: //www.ncbi.nlm.nih gov). 
 
2.6 Gene expression 
 
Evaluation of gene expression was performed by quantitative real time PCR 
(qRT-PCR). Optimal concentrations of primers to use in qRT-PCR were determined 
after evaluating the highest fluorescence signal in the shortest Cycle threshold (Ct). 
To determine the efficiency of the PCR reactions, standard linear curves were made 
for all pairs of primers, using 8 dilutions of 0.05 to 50 ng/μL from an initial mixture of 
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cDNA. The slope of the regression lines was used to evaluate PCR efficiency. qPCR 
was performed in an Eppendorf Mastercycler realplex 4 qPCR system (Eppendorf, 
Hamburg, Germany). The following components and volumes were placed in each 
well: 10µL of SybrGreen (Biorad), 4µL of water, 2µL of forward primer, 2µl of reverse 
primer and 2µL of cDNA in a total volume of 20µL. All the reactions were performed in 
duplicate using the following protocol: 1 cycle at 95ºC for 3 min followed by 40 cycles 
at 95ºC for 10 sec; 51ºC, 54ºC or 55ºC (51ºC to VMAT, 55ºC to receptor of serotonin 
5-HT-2C and dopamine drd1b; 54ºC for the remaining genes) for 30 sec; and 72ºC for 
30 sec. A blank sample was performed for each gene studied as well as a melting 
curve in order to check for the formation of nonspecific products. Quantitation of gene 
expression was performed by normalizing to reference genes actb1 and rpl8 for 
norfluoxetine and the cocktail and ef1 and rpl8 for venlafaxine as determined using 
the Normfinder algorithm (Urbatzka et al., 2013). Relative expression was calculated 
using the efficiencies of the real-time qPCR using the mathematical template of Pfaffl 
(Pfaffl., 2001). 
 
2.7 Data analysis  
  
Differences between treatments in the embryo toxicity assay were evaluated by 
means of crosstable χ2 test at 5% significance level, avoiding repeated measures 
designs to fulfil test assumptions. Data is presented as mean ± standard error of the 
mean (SE) of malformation frequencies obtained in the three independent replicates.  
Differences in mRNA expression were evaluated by means of a one-way analysis of 
variance (ANOVA), followed by a Dunnett’s test at a 5% significance level. Data were 
log-transformed in order to fit ANOVA assumptions. When ANOVA assumptions could 
not be met after transformation, the non-parametric Kruskal-Wallis test was used to 
investigate differences in expression among treatments. 
A Principal Component Analysis (PCA) to search for specific responses patterns 
among genes evaluated and associate them with exposure conditions. Factor maps 
were generated for individuals (with calculation of confidence ellipses) and variables 
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to assist results interpretation, respectively. PCA was performed using FactoMineR 
package developed by Lê and colleagues (Lê et al., 2008). 
Hierarchical cluster analysis (HCA) was also applied to further depict 
relationships among genes assayed. HCA was based on the Pearson correlation 
coefficient with single linkage, using GENE-E software available at the Broad Institute 
(http://www.broadinstitute.org). Gene expression was plotted into a heatmap 
according to HCA results, using GENE-E.  
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3.1. Embryonic exposure to norfluoxetine 
3.1.1. Mortality and gross malformations 
 
 Results of the toxicity tests carried out showed that mortality was generally low in 
both the control and the exposed groups (Figure 10). Average cumulative mortality 
recorded was always below 15%. Though, a statistically significant reduction of 
average cumulative mortality was observed at 8hpf in zebrafish embryos exposed to 
16 ng/L norfluoxetine in relation to controls. At 32 and 80 hpf this difference was no 
longer detected (Figure 10). 
 
Figure 10. Cumulative mortality of embryos exposed to different concentrations of norfluoxetine at 
different developmental stages. Values represent the mean ± SE of three independent replicates. 
Significant differences (p<0.05) in relation to the control are marked with an asterisk. Significant 
differences (p<0.5) at 32 and 80hpf, relative to the respective treatment at 8hpf, are marked with #. 
 
   At 32 and 80hpf recorded average cumulative mortality was significantly higher 
than at 8hpf in all treatments tested, except in the 80ng/L concentration. No additional 
mortality was detected between 32 and 80 hpf (Figure 10). 
   In contrast to the results observed for mortality, the total number of anomalies 
found increased over time in zebrafish embryos exposed to norfluoxetine (Figure 11).  
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Figure 11. Rate of gross malformations in embryos exposed to different concentrations of norfluoxetine 
at different developmental stages. Significant differences (p<0.5) in relation to control are marked with an 
asterisk. Significant differences (p<0.5) at 32 and 80hpf, relative to the respective treatment at 8hpf, are 
marked with #. 
 
   At 32hpf, significant increases in the frequency of malformations were found for 
0.64 and 400ng/L norfluoxetine treatments, compared to the frequency observed in 
the respective treatments at 8hpf. At the end of the test, the frequency of embryo 
malformations was significantly higher in all norfluoxetine concentrations, compared 
to the control group (Figure 11). The 80ng/L norfluoxetine treatment was the one 
showing higher number of anomalies at 80hpf. The significant differences in relation 
to the control, resulted from an increase in occurrence of different anomalies, 
although statistically significant differences could only be found for delay in 
pigmentation (Figure 12). 
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Figure 12. Total of pigmentation anomalies found at 80hpf and illustrative example of the anomaly. 
Significant differences in relation to the control are marked with an asterisk. In bottom left is indicated a 
control and at bottom right is indicated a pigmentation anomaly observed in treated larvae.   
 
3.1.2. Molecular responses 
Reference genes 
 
   A multiple reference gene approach was employed in this work. The selection of 
reference genes for this approach was based on the software NormFinder 
(model-based approach). Higher stability in mRNA expression among groups is 
indicated by values closer to zero. NormFinder evaluated rpl8 as the most stable gene 
(stability value: 0.005) if used as single reference gene, and actb1 + rpl8 (stability 
value: 0.005) as the most stable combination for multiple reference genes, since 
combination of genes with intergroup variations orientated in opposite directions is 
recommended. Hence, for norfluoxetine experimental data, mRNA expression of the 
genes tested was corrected by the normalization factor of rpl8+actb1. 
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Expression of receptor, transporter, biotransformation and antioxidant genes 
 
   Figure 13 presents gene expression levels obtained for the serotonin transporter 
serta and serotonin receptors 5-ht2c and 5-ht1a. Globally, expression levels 
determined for these genes were similar among treatments. The only exception was 
5-ht2c for which induction of expression was found in larvae exposed to 80ng/L 
norfluoxetine (p<0.05). 
   Patterns of transcription of dopaminergic genes after exposure to norfluoxetine are 
shown in Figure 14. For dat, there was an apparent tendency for induction of gene 
transcription, although no significant differences between norfluoxetine and control 
groups could be found. For drd1b and drd2b, expression levels of larvae exposed to 
norfluoxetine were comparable to those of control organisms (Figure 14).  
 
 
Figure 13. Expression of serotonergic genes after exposure to different concentrations of norfluoxetine 
for 80hpf. Significant differences (p<0.05) in relation to the control are marked with an asterisk.  
 
   Figure 15 presents gene expression data for norepinephrine transporter net and 
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norepinephrine receptors adra2a, adra2b and adra2c. In contrast to the remaining 
genes, Adra2a and adra2c show tendency for inhibition of transcription. Significantly 
lower (p<0.05) expression was found for adra2c at the lowest concentration of 
norfluoxetine tested (0.64ng/L), compared to the control group (Figure 15). 
   Expression of genes vmat2 and mao is plotted in Figure 16. These genes 
appeared to exhibit a trend for opposite variation; inhibition for vmat2 and induction for 
mao. Nevertheless, no significant differences in expression in relation to the control 
could be found for either gene. 
 
 
Figure 14. Expression of dopaminergic genes after exposure to different concentrations of norfluoxetine 
for 80 hpf. 
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Figure 15. Expression of noradrenergic genes after exposure to different concentrations of norfluoxetine 
for 80 hpf. Significant differences (p<0.05) in relation to the control are marked with an asterisk. 
 
 
Figure 16. Gene expression of vmat2 and mao after exposure to different concentrations of norfluoxetine 
for 80 hpf. 
 
   The pattern of transcription of nuclear receptors pxr and ahr2 obtained after 
exposure to norfluoxetine is shown in Figure 17. Though some variation among 
treatments was observed for pxr, sometimes suggesting inhibition and other times 
suggesting induction, no significant differences in expression could be depicted. For 
ahr2, levels of expression in norfluoxetine treatments were similar to those of the 
control.  
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Figure 17. Gene expression of nuclear receptors pxr and ahr2 after exposure to different concentrations 
of norfluoxetine for 80 hpf 
 
   Expression of raraa and rarab nuclear receptors of larvae exposed to norfluoxetine 
was similar to control levels (Figure 18). On the other hand, rarga presented a 
different expression response to norfluoxetine exposure. rarga expression level 
increased at low exposure concentrations, peaking at 3.2 ng/L norfluoxetine for which 
statistically significant differences relative to the control group were found (p<0.05). 
Thereafter, expression levels decreased to near control values.  
 
Figure 18. Gene expression of rar group of nuclear receptors after exposure to different concentrations 
of norfluoxetine for 80 hpf. Significant differences (p<0.05) in relation to the control are marked with an 
asterisk. 
* 
38 
 
 
   Figure 19. presents gene expression data of rxr group of nuclear receptors. 
Expression of genes of this group in larvae exposed to norfluoxetine was similar to 
that of controls, as indicated by ratios of relative mRNA expression around the unit.  
 
 
Figure 19. Gene expression of rxr group of nuclear receptors after exposure to different concentrations 
of norfluoxetine for 80 hpf 
 
The pattern of transcription of ppar group of nuclear receptors obtained after exposure 
to norfluoxetine is shown in Figure 20. Interestingly, also for this group no significant 
differences in gene expression were found among treatments, suggesting these were 
not affected by norfluoxetine during embryonic development. 
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Figure 20. Gene expression of ppar group of nuclear receptors after exposure to different concentrations 
of norfluoxetine for 80 hpf 
 
     Similarly, gene expression of abcc2 and abcg2a transporters, showed no 
obvious pattern of induction or inhibition (figure 21). For abcb4, low exposure (0.64 
ng/L) caused inhibition of expression (p<0.05) that was no longer observed at 
concentrations ≥3.2 ng/L. Conversely, larvae exposed to 3.2 ng/L showed induction 
(p<0.05) of abcc1 expression. For the remaining test concentrations, expression 
levels were within control values. 
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Figure 21. Gene expression of ABC transporters (Phase 0 / III) after exposure to different norfluoxetine 
concentrations for 80 hpf. Significant differences (p<0.05) in relation to the control are marked with an 
asterisk. 
 
   Like observed for other genes, no clear pattern of alteration of gene expression by 
norfluoxetine was visible for most biotransformation and antioxidative enzymes 
evaluated (Figures 22 and 23). Apart from sod, no differences in expression levels 
were detected among treatments for cyp1a1, cyp3a65, gstπ and cat. For Cu/Zn sod 
significant transcriptional inhibition was found in organisms exposed to high (400 ng/L) 
norfluoxetine concentration (p<0.05).      
 
* 
* 
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Figure 22. Gene expression of biotransformation enzymes (phase I and II) after exposure to different 
norfluoxetine concentrations for 80 hpf. 
 
 
Figure 23. Gene expression of oxidative stress enzymes after exposure to different norfluoxetine 
concentrations for 80 hpf. Significant differences (p<0.05) in relation to the control are marked with an 
asterisk. 
 
   Main patterns of variation in gene expression are summarized in Figure 24 in the 
form of a heatmap. The heatmap is colour-coded according to the percentage of 
variation relative to the control group. The levels of most genes were found to be fairly 
stable across exposure concentrations. Nevertheless, hierarchical cluster analysis 
identified a group of concentrations sharing some similarity in gene expression. This 
group comprised 16, 0.64, 400 and 80 ng/L norfluoxetine. The group showed a 
* 
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tendency for slight inhibition several genes, such as abcg2a, rxrbb, rxrxgb and adra2c, 
and slight induction of dat, serta and net. The concentration of 3.2ng/L was 
associated with an inverse expression response of these genes. 
 
Figure 24. Heatmap of gene expression variation in organisms exposed to different concentrations of 
norfluoxetine for 80hpf. The colour scale reflects the direction and magnitude of variation in relation to the 
control group. The asterisk indicates significant differences relative to the control at p < 0.05. 
 
   For more detailed investigation of the patterns of response of the genes evaluated, 
and their possible association to exposure concentrations, PCA analysis was then 
43 
 
carried out. According to results obtained, seven components were extracted, 
expressing 87% of the total variability observed in the data. Of these, the first two 
principal components (PCs) retained 60% of the total inertia (Figure 25). Interpretation 
of PCA results was, therefore, based on the first two components extracted. The first 
component (horizontal) was mainly associated with the expression of genes involved 
in detoxification and to a lesser extent with monoamine transporter and receptors: 
rxrga and rxrgb, showing positive correlations (r) with the axis above 0.90; with rxrab, 
raraa, serta, cyp3a65, rarab, pparg, rxrbb, rxraa all with r>0.8; with net, mao, cyp1a1, 
5-ht1a and pparβ all with r>0.7; and with pxr, gstπ, sod, pparα, rarga, adra2b, dat 
and ahr2 (r>0.6). This pattern is visible in the variables factor map of Figure 25. The 
second axis (vertical) was mainly associated with the expression of dopamine and 
serotonin receptors and two ABC transporters: drd1b, 5-ht2c, abcg2a and abcc1 all 
positively correlated with the axis (r>0.6). Analysis of the individuals factor map 
(Figure 25) shows no remarkable differences between the control group and the 
concentrations of norfluoxetine tested. Centroids for 3.2 and 80 ng/L concentrations 
were the most distant from the control, however the confidence ellipses of these three 
groups are intersected.   
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Figure 25. Results of the PCA defined by the expression of genes evaluated in zebrafish larvae exposed 
to norfluoxetine for 80hpf. The cloud of genes is represented in the variables factor map; sample are 
represented in the individuals factor map (bottom). Centroids of each treatment group, and respective 
confidence ellipses, are also shown. 
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3.2. Embryonic exposure to venlafaxine 
3.2.1. Mortality and gross malformations 
 
 Mortality recorded during the toxicity tests performed was very low, particularly in 
the control group (Figure 26). Cumulative mortality was below 5% in all test 
treatments at 8 hpf.  
 
Figure 26. Cumulative mortality of embryos exposed to different concentrations of venlafaxine at 
different developmental stages. Values represent the mean ± SE of three independent replicates. 
Significant differences (p<0.05) relative to 8 hpf are marked with #. 
 
   A slight increase in cumulative mortality, to about 10% on average, was recorded 
at 32hpf in the control and in embryos exposed to 80 and 400ng/L venlafaxine, 
compared to the respective groups at 8hpf (p<0.05) (Figure 26). After this point, no 
additional dead embryos were found. The highest cumulative mortality was always 
observed in the group exposed to a venlafaxine concentration of 400ng/L, 
independently of the time window assessed.  
In contrast to the results observed for mortality, a high rate of malformations was 
detected. At 8hpf the frequency of malformations was very low (≤5%) (Figure 27). 
Controls continued to exhibit low frequency of malformations (<10%) over time. 
However, in exposed embryos, a clear tendency for increase in malformations with 
the increase in venlafaxine concentration was evident at 32pf.  
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Figure 27. Gross malformations in embryos exposed to different concentrations of venlafaxine at 
different analysis points. Significant differences in relation to the control are marked with (*) and relative 
to 8 hpf with (#), with p <0.05 
 
   At 32 hpf significant increases (p<0.05) in the number of anomalies were found in 
all venlafaxine concentrations in relation to the previous developmental window 
analysed (8 hpf). Significant differences relative to the control group were found for 
the highest concentrations tested (400, 2000 and 10000ng/L). Malformations 
contributing to this increase were a delay in the pigmentation and anomalies in the 
vitelline sac (Figure 28) 
 
Figure 28. Frequency of total and pigmentation and vitelline sac anomalies found at 32 hpf. Normal 
embryo is indicated by C (left) and an example of anomalies observed (right) indicative by the red arrow. 
Significant differences (p<0.05) in relation to the control are marked with an asterisk. 
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   At the end of the test (80 hpf), with individuals already in larval stage, statistically 
relevant increases (p<0.05) in the rate of malformations, in relation to the control 
group, were found for exposure concentration ≥ 80ng/L venlafaxine. In these 
treatments the rate of total anomalies ranged on average from 20% (80ng/L group) to 
30% (10000 ng/L). Delayed pigmentation and spinal anomalies were the 
malformations contributing mostly to the pattern observed (Figure 29). 
 
 
Figure 29. Frequency of total pigmentation and spine/tail anomalies found at 80 hpf. Normal embryo is 
indicated by C (left) and an example of anomalies observed (right) indicative by the red arrow. Significant 
differences (p<0.05) in relation to the control are marked with an asterisk. 
 
 
3.2.2. Molecular responses 
 
Reference genes 
 
   NormFinder evaluated rpl8 as the most stable gene (stability value: 0.005) if used 
as single reference gene. The combination of ef1 and rpl8 (stability value: 0.006) was 
found to be the most for multiple reference genes. mRNA expression of the genes 
evaluated after venlafaxine exposure was therefore corrected by the normalization 
factor of rpl8 + ef1. 
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Expression of receptor, transporter, biotransformation and antioxidant genes 
 
Figure 30. presents the gene expression of serotonin transporter serta and serotonin 
receptors 5-ht2c and 5-ht1a. Globally, there was a clear tendency for inhibition of 
transcription of all these genes, though with different trends. For the serotonin 
transporter serta, the group exposed to 10000ng/L exhibited the highest inhibition 
(p<0.05), of more than half the control level. Conversely, expression of 5-ht2c receptor 
increased in the lowest test concentration (16ng/L) relative to the control, decreased 
thereafter to levels well below control at 80 (p<0.05) and 400ng/L (p<0.05), then 
recovering to controls levels. For serotonin receptor 5-ht1a, significant inhibition was 
found at 10000ng/L venlafaxine (p<0.05) (Figure 30).  
 
 
Figure 30. Gene expression of serotonergic genes after exposure to different concentrations of 
venlafaxine for 80 hpf. Significant differences in relation to the control are marked with (*)  
 
   Patterns of transcription of dopaminergic genes after exposure to venlafaxine are 
shown in Figure 31. Dopamine transporter dat was induced at lower concentrations, 
peaking in larvae exposed to 400ng/L (p<0.05). In larvae exposed to high venlafaxine 
concentrations it was near control expression levels. Receptor drd1b showed an 
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opposite trend; expression was decreased in organisms exposed to the lower 
venlafaxine concentrations, with significant differences relative to the control at 80 and 
400ng/L (p<0.05). In the highest test concentrations there was a recovery to control 
levels, in a U-shape response curve (Figure 31). For drd2b, no significant alterations 
were found in venlafaxine treatments, in relation to control expression levels; the 
values of exposed organisms were similar to those of the control group. 
 
 
Figure 31. Gene expression of dopaminergic genes after exposure to different concentrations of 
venlafaxine for 80 hpf. Significant differences in relation to the control are marked with (*)  
 
   Figure 32. presents the gene expression of norepinephrine transporter net and 
norepinephrine receptors adra2a, adra2b and adra2c. For net, trend of inhibition of 
transcription was visible in organisms exposed to venlafaxine. Statistically significant 
differences relative to the control were found for the highest concentration tested 
(10000ng/L) (p<0.05). For adra2b, there was a clear induction of gene expression, 
with organisms exposed to ≥400ng/L showing significant 2-3 fold increases in 
expression (p<0.05). No significant differences among treatments were detected for 
the expression levels of either adra2a or adra2c.  
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Figure 32. Gene expression of noradrenergic genes after exposure to different concentrations of 
venlafaxine for 80 hpf. Significant differences in relation to the control are marked with (*) 
 
   Gene expression of vmat2 and mao genes is shown in Figure 33. vmat2 
expression appeared to increase in larvae exposed to the lowest concentration 
(16ng/L), followed by significant inhibition (p<0.05) of the gene transcription at 80 and 
400 ng/L. At 2000ng/L and 10000 ng/L expression levels in exposed larvae were in 
the same range of those of control larvae. For mao inhibition of gene expression 
(p<0.05) was also observed in larvae exposed to the highest concentration of 
venlafaxine. No differences in mao expression were found between the controls and 
the remaining treatments.  
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Figure 33. Gene expression of vmat2 and mao after exposure to different concentrations of venlafaxine 
for 80 hpf. Significant differences in relation to the control are marked with (*) 
 
   The patterns of transcription of nuclear receptors pxr and ahr2 after exposure to 
venlafaxine are shown in Figure 34. No significant differences among treatments were 
observed for either gene. 
 
 
Figure 34. Gene expression of nuclear receptors pxr and ahr2 after exposure to different concentrations 
of venlafaxine for 80 hpf 
 
   Likewise, no effects of venlafaxine exposure on retinoic acid receptors could be 
depicted (Figure 35.).  
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Figure 35. Gene expression of rar group of nuclear receptors after exposure to different concentrations 
of venlafaxine for 80 hpf 
 
   In contrast, exposure to venlafaxine caused inhibition of rxrab (p<0.05) and rxrga 
(p<0.05) expression in organisms exposed to 400 ng/L, compared to control 
organisms. Relative to the control group, significant inhibition of gene expression was 
also found for rxrgb in organisms exposed to 400ng/L (p<0.05) and 10000ng/L 
(p<0.05). No differences in exposed larvae were found for the expression of the other 
two retinoic x receptors evaluated (rxraa and rxrbb) when compared to controls. 
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Figure 36. Gene expression of rxr group of nuclear receptors after exposure of zebrafish to different 
concentrations of venlafaxine for 80 hpf. Significant differences in relation to the control are marked with 
(*) 
 
   Patterns of transcription of ppar nuclear receptors after exposure to venlafaxine 
are shown in Figure 37. For this group of genes a U-shape response to venlafaxine 
exposure was visible. Significant inhibition of gene expression, relative to control, was 
found for pparα at 400 ng/L (p<0.05), for pparβ at 80 ng/L (p<0.05) and 400ng/L 
(p<0.05), and for pparγ at 80 ng/L (p<0.05), 400 ng/L (p<0.05) and 2000 ng/L (p<0.05) 
(Figure 37). For all genes the 400ng/L concentration was the one where the inhibition 
was more accentuated. 
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Figure 37. Gene expression of ppar group of nuclear receptors after exposure to different concentrations 
of venlafaxine for 80 hpf. Significant differences in relation to the control are marked with (*) 
 
   Patterns of transcription of ABC transporters after exposure to venlafaxine are 
shown in Figure 38. For abcg2a and abcc1 a clear U-shape response pattern was 
observed. Compared to the control group, inhibition of gene expression was observed 
at 80 (p<0.05) and 400ng/L (p<0.05) venlafaxine concentrations for abcg2a, and at 
400ng/L (p<0.05) for abcc1. For abcb4, larvae exposed to 2000ng/L concentration 
also exhibit inhibition of gene expression when compared to control larvae (p<0.05) 
(Figure 38.). No relevant differences among treatments were found for abcc2 
expression.  
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Figure 38. Gene expression of ABC transporters (Phase 0 / III) after exposure to different venlafaxine 
concentrations at 80 hpf. Significant differences in relation to the control are marked with (*) 
 
   Figure 39. presents the gene expression for biotransformation enzymes 
determined after exposure to venlafaxine for 80hpf. For phase I enzymes, cyp3a65 
expression was significantly decreased (p<0.05) in organisms exposed to 10000 ng/L 
venlafaxine, compared to the control group. No other alterations in gene expression 
were found, including for cyp1a1 and phase II biotransformation enzyme gstπ. Gene 
expression of antioxidant enzyme Cu/Zn sod also showed a trend for decreased 
expression, which was significantly inhibited in the 10000ng/L group (p<0.05), 
compared to the control (Figure 40.). Levels of cat expression in exposed organisms 
were fairly stable, compared to those of control larvae. 
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Figure 39. Gene expression of biotransformation enzymes (phase I and II) after exposure to different 
venlafaxine concentrations at 80 hpf. Significant differences in relation to the control are marked with (*) 
  
 
Figure 40. Gene expression of oxidative stress enzymes after exposure to different venlafaxine 
concentrations for 80 hpf. Significant differences in relation to the control are marked with (*) 
 
   A summary of the pattern of variation of gene expression obtained in the 
venlafaxine assays is shown in the heatmap of Figure 41. In contrast to norfluoxetine, 
where slight tendency for upregulation was observed, the heatmap for venlafaxine 
shows the clear tendency for downregulation of gene expression identified previously, 
as indicated by the prevalence of colder colours. Genes for which higher 
downregulation was observed were: abcg2a, abcc1, drd1b, ppar receptors, 5-ht2c, 
vmat2, sert, net and 5-ht1a. On the other hand, adra2b was the gene showing the 
* 
* 
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highest level of induction. Apart from this, upregulation was only observed for dat, 
though in a very low level. Hierarchical cluster analysis identified two groups of 
concentrations sharing some similarity in gene expression (Figure 41.). The first 
group aligned together concentrations of 80, 400 and 2000 ng/L venlafaxine. Here 
abcg2a and abcc1 transporters, ppar nuclear receptors, drd1b and 5-ht2c showed 
resembling patterns of expression, characterized particularly by downregulation. The 
second group aligned together the most extreme concentrations (16 and 10000 ng/L), 
confirming the U-shape response described above. Most genes in this group showed 
no alterations relative to control or very slight downregulation, in contrast to the former 
group. 
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Figure 41. Heatmap of gene expression variation in zebrafish early larvae after exposure to different 
concentrations of venlafaxine for 80hpf. The colour scale reflects the direction and magnitude of variation 
in relation to the control group. The asterisk indicates significant differences relative to the control at 
p < 0.05. 
 
In the PCA performed for this dataset seven components were extracted, expressing 
88% of the total variability in the data. Of these, the first two principal components 
(PCs) retained 51% of the total inertia (Figure 42). The first component was mainly 
associated with the expression of ABC transporters, dopamine and serotonin 
receptors, and several nuclear receptors related to the detoxification process: 
drd1b (r>0.9); abcg2a, pparγ, pparβ showing correlation with the axis above 0.8; 
59 
 
abcc2, pparα, 5-ht2c and gstπ with r>0.7; abcc1, vmat2, rxraa, cyp1a1, rxrab and 
raraa with r>0.6. This axis clearly separated the control group from the 400 ng/L 
treatment, which tend to show upregulation of adra2b and downregulation of abcc2, 
abcg2a, abcc1, ppar nuclear receptors, drd1b and vmat2 (Figure 42). In the 
venlafaxine treatment, the second axis was mainly associated with the expression of 
monoamine transporters and receptors: net, serta and dat, showing correlation with 
the axis above 0.7; and with 5-ht1a, rxrga, adra2a and mao (r>0.6). This axis further 
discriminated the highest test treatment (10000ng/L) from the remaining groups. 
 
 
 
60 
 
 
 
Figure 42. Results of the PCA defined by the expression of genes evaluated in zebrafish larvae exposed 
to venlafaxine for 80hpf. The cloud of genes is represented in the variables factor map; sample are 
represented in the individuals factor map (bottom). Centroids of each treatment group, and respective 
confidence ellipses, are also shown. 
 
3.3 Exposure to a cocktail of psychotropic drugs 
3.3.1. Mortality and gross malformations 
 
   Results of the embryo toxicity assays performed with the cocktail of norfluoxetine 
and venlafaxine showed this combination elicited a higher rate of mortality in relation 
to control in all time windows of embryonic development of zebrafish analysed (Figure 
43.). In comparison to organisms exposed to the single compound, the mixture also 
showed an increase in the mortality rate. However, no differences were found 
between mortality at 8 hpf and the following time windows evaluated. Observation of 
Figure 43. also shows that mortality in the cocktail occurred just until 32hpf, because 
no dead embryos were found between 32 and 80hpf in any of the test conditions. 
Results obtained for the single compounds are in the same range of those presented 
in the previous sections.  
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Figure 43. Cumulative mortality of embryos exposed to 3.2ng/L of norfluoxetine, 2000ng/L of venlafaxine 
and to a mixture of both. Significant differences (p<0.05) in relation to the control are marked with *; 
differences relative to 8 hpf are indicated with #. 
 
   Regarding the gross anomalies found, the cocktail showed different results, 
according to the time window analysed (Figure 44.). At 8 hpf embryos anomalies were 
seldom observed in any test group. At 32 hpf the paradigm changes and embryos 
exposed to the single compounds or the mixture had a significant increase in the total 
of anomalies found in relation to the respective control and also in relation to the 
respective test group at 8 hpf. Embryos exposed to the mixture were the ones 
presenting more anomalies, mainly due to anomalies in pigmentation (Figure 45.), 
pointing out a possible synergetic relationship between both pharmaceuticals. 
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Figure 44. Gross malformations in embryos exposed to 3.2ng/L of norfluoxetine, 2000ng/L of venlafaxine 
and to a mixture of both psychotropic drugs. Significant differences (p<0.05) in relation to the control are 
marked with *; significant differences relative to 8 hpf are marked with #. 
 
At 80 hpf, the frequency of malformations exhibited by embryos exposed to single 
compounds was still higher than that of controls. The frequency of malformations 
detected in embryos exposed to the cocktail was similar to that of the control group 
(Figure 44.), pointing out a possible antagonist effect between both pharmaceuticals 
in this development period. Globally, in relation to embryos exposed to single 
compounds, the results are similar to those obtained in the previous sections of this 
work. Though, in this case, for the norfluoxetine treatment a significant increase in the 
anomalies was visible at 32hpf, in relation to control and 8hpf.  
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Figure 45. Total of pigmentation anomalies found at 32hpf and illustrative example of the anomaly. 
Significant differences in relation to the control are marked with an asterisk. (C) indicates a control at 
bottom right is indicated a pigmentation anomaly observed in treated embryo.   
 
3.3.2. Molecular responses 
 
   Genes evaluated in the cocktail experiments were selected from those showing 
relevant alterations in the previous experiments. Reference genes were evaluated 
simultaneously with the genes of interest and their stability was investigated with 
NormFinder as described previously. The results obtained are described in the 
following subsections.  
 
Reference genes 
 
   NormFinder evaluated actb1 as the most stable gene (stability value: 0.008) if 
used as single reference gene. The combination of actb1 and rpl8 (stability value: 
0.007) was found to be the most for multiple reference genes, due to opposite 
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intergroup variation. mRNA expression of the genes evaluated after venlafaxine 
exposure was therefore corrected by the normalization factor of actb1 + rpl8. 
 
Expression of monoamine receptors, nuclear receptors and ABC transporters 
 
   Figure 46. presents the gene expression of neurohormonal receptors 5-ht2c, 
drd1b and adra2b involved in norfluoxetine and venlafaxine mode of action. The 
results show that embryos exposed to the mixture of norfluoxetine and venlafaxine 
suffered an inhibition of expression of 5-ht2c (p<0.05) and drd1b (p<0.05) genes.  
 
Figure 46. Gene expression of neurohormonal receptors in embryos exposed to 3.2ng/L of norfluoxetine, 
2000ng/L of venlafaxine and to a mix of both previous mentioned concentrations and compounds. 
Significant differences in relation to the control are marked with an asterisk (*). 
 
    In comparison to exposure to single compounds, embryos exposed to the mixture 
exhibited inhibition of gene expression previously observed for venlafaxine. Focusing 
only in the embryos exposed to single compounds, the results are within the response 
range obtained in previous sections of the work. Interestingly, for adra2b, despite a 
significant increase observed for venlafaxine, exposure to the cocktail resulted in 
inhibition of expression (p<0.05). These results suggest an antagonistic effect of these 
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two psychotropic drugs. 
   Figure 47. presents the gene expression of vmat2. The results show that embryos 
exposed to the mixture of 3.2ng/L of norfluoxetine and 2000ng/L of venlafaxine suffer 
a statistically significant inhibition of expression (p<0.05). Like for the neurohormonal 
receptors, in comparison to exposure to the compounds alone, embryos exposed to 
the mixture suffered inhibition of gene transcription, showing effects even when 
exposure to single compounds elicited no alterations, relative to the control.  
 
 
Figure 47. Gene expression of vmat2 in embryos exposed to 3.2ng/L of norfluoxetine, 2000ng/L of 
venlafaxine and to a mix of both previous mentioned concentrations and compounds. Significant 
differences in relation to the control are marked with (*) 
 
   The pattern of transcription of ppar group of nuclear receptors after exposure to 
3.2 ng/L of norfluoxetine, 2000ng/L of venlafaxine and a mixture of both 
concentrations is shown in Figure 48. The results showed that embryos exposed to 
the mixture of 3.2ng/L of norfluoxetine and 2000ng/L of venlafaxine suffer different 
responses in ppar genes (p<0.05).  
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Figure 48. Gene expression of ppar group of nuclear receptors in embryos exposed to 3.2ng/L of 
norfluoxetine, 2000ng/L of venlafaxine and to a mix of both previous mentioned concentrations and 
compounds.  
 
   For pparγ inhibition of gene expression was visible for the venlafaxine treatment, 
while for the mixture no differences relative to the control could be found (Figure 48), 
again suggesting an antagonistic effect of the two test substances. For the remaining 
ppar nuclear receptors, no differences among treatments were found. Focusing only 
in embryos exposed to the single compounds, the results for both substances are in 
the response range obtained in previous sections of the work. 
   Patterns of transcription of ABC transporters after exposure to 3.2 ng/L of 
norfluoxetine, 2000ng/L of venlafaxine and a mixture of both concentrations and 
compounds are shown in Figure 49. The results showed that embryos exposed to the 
mixture of 3.2ng/L of norfluoxetine and 2000ng/L of venlafaxine had different 
responses of ABC transporters. For abcc2 there was an induction of gene expression 
following exposure to 3.2ng/L norfluoxetine (p<0.05), but no effect of the mixture, 
compared to the control group. For abcc1 there was a clear induction of transcription 
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after exposure to norfluoxetine alone (p<0.05) and inhibition of transcription after 
exposure to venlafaxine alone (p<0.05). However, no significant differences relative to 
the control were found after expression to the cocktail evaluated. 
 
 
Figure 49. Gene expression of ABC transporters (Phase 0 / III) in embryos exposed to 3.2ng/L of 
norfluoxetine, 2000ng/L of venlafaxine and to a mix of both previous mentioned concentrations and 
compounds. Significant differences in relation to the control are marked with (*) 
 
   Comparing the results obtained in the mixture those of exposures to single 
compounds, embryos exposed to 2000ng/L of venlafaxine suffered an inhibition but a 
recuperation to values close to the control was visible in the mixture which had an 
intermediate gene expression value between norfluoxetine and venlafaxine. These 
results again suggest an opposite effect of the two substances when provided 
together.  
   The hierarchical cluster analysis (HCA) for embryos exposed to 3.2ng/L of 
norfluoxetine, 2000ng/L of venlafaxine and to a mix of both show some differences 
among tested genes. A summary of the variation in gene expression observed is 
shown in the heatmap of Figure 50. The clusters identified show differences between 
genes involved in the detoxification mechanisms and neurohormonal receptors. Also, 
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expression of adra2b is different from all the other tested genes. The heat map shows 
a general tendency for inhibition in the 2000ng/L venlafaxine treatment, relative to 
control. The norfluoxetine (3.2ng/L) and the mixture treatments were grouped 
together by the HCA. These show opposite responses to the venlafaxine treatment. 
For norfluoxetine, no alterations or slight induction of gene expression were prevalent. 
For the mixture, neurohormone genes were the most affected, showing inhibition of 
expression (Figure 50). The higher levels of inhibition of neurohormonal receptors in 
the mixture in relation to single compounds is clear in the heatmap. In addition to this, 
for ABC transporters and ppar genes it is also visible the tendency for the mixture to 
have intermediate values of expression, between those obtained for single exposure 
to venlafaxine or norfluoxetine.  
 
Figure 50. HCA and heatmap for embryos exposed exposed to 3.2ng/L of norfluoxetine, 2000ng/L of 
venlafaxine and to a mix of both previous mentioned concentrations and compounds for 80h. The 
asterisk indicates significant differences relative to the control at p < 0.05. 
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   The analysis of the PCA individuals factor map showed differences between the 
control group and the some of the concentrations tested. Individuals exposed to 
3.2ng/L of norfluoxetine only, didn’t show differences in relation to control since the 
ellipses of both group intersect with each other (Figure 51.). The same didn’t happen 
in individual exposed to 2000ng/L of venlafaxine and to the mixture of 3.2ng/L of 
norfluoxetine and 2000ng/L of venlafaxine, where ellipses didn’t intersect with the 
control group. The mixture seems to be more different from control than the 
venlafaxine concentration alone, however, this can be explained by the greater 
cohesion of the values obtained in the mixture. 
 
Figure 51. Results of the PCA defined by the expression of genes evaluated in zebrafish larvae exposed 
to norfluoxetine (3.2ng/L), venlafaxine (2000ng/L) and a mixture of both for 80hpf. The cloud of genes is 
represented in the variables factor map; samples are represented in the individuals factor map (bottom). 
Centroids of each treatment group, and respective confidence ellipses, are shown. 
 
 In the PCA performed for cocktail dataset three components were extracted, 
expressing 84% of the total variability in the data. The first two components explained 
high a proportion (73%) of the total inertia (Figure 51.). The analysis to the variables 
factor map show interesting patterns of expression of tested genes in embryos 
exposed to 3.2ng/L of norfluoxetine, 2000ng/L of venlafaxine and to a mixture of both. 
The first component was associated with the expression of ABC transporters, ppar 
nuclear receptors and serotonin and dopamine receptors as well. The component 
significantly differentiated norfluoxetine and venlafaxine treatments (Figure 51). In the 
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map there are visible differences between genes involved in the mode of action of the 
studied drugs (drd1b, vmat2 and 5-ht2c) and genes involved in detoxification 
mechanisms (ppar receptors and abc transporters genes). The second component 
opposed the adrenergic and dopaminergic receptors to pparβ. This axis significantly 
discriminated the venlafaxine treatment from the cocktail (Figure 51). Moreover, 
adra2b is clearly separated from all the others assessed. Looking to the map, one can 
also observe a strong positive correlation between some specific genes like vmat2 
and drd1b or pparα and abcg2a, that have almost equal representation.  
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Chapter 4: Discussion 
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4.Discussion 
 
The use of embryos of aquatic organisms in bioassays, is useful and effective since 
the early stages of development are usually more sensitive than other life cycle 
phases. They also allow to monitor parameters that otherwise would be impossible to 
analyse later in life. In this study two different kinds of antidepressants were evaluated, 
a SSRI (norfluoxetine) and a SNRI (venlafaxine), single and in mixture. Study of 
pharmaceutical metabolites is very pertinent since they are often active, exhibiting 
pharmacological properties. However, investigation of these compounds has been 
neglected in scientific studies (Evgenidou et al., 2015). In this work, the choice felt on 
norfluoxetine because this is an active metabolite of a very well-known and studied 
parental compound (fluoxetine). Moreover, in recent studies it is the most 
representative metabolite found in Portugal (Santos et al., 2016). Venlafaxine was 
chosen because it is widely prescribed all over the world and is found in aquatic 
systems in relatively high concentrations, in relation to other antidepressants like 
fluoxetine (Schultz et al., 2010; Gonzalez Alonso et al., 2010). 
The study of the action of multiple substances has also great environmental relevance 
given that in the environment the most common situation is the presence of several 
compounds that interact to each other (Evgenidou et al., 2015). Despite its 
importance, knowledge about the action of mixtures of substances is still scarce and, 
thus, the reason why testing a mixture of these drugs was considered very relevant in 
the scope of this work. 
The results obtained in this work, showed that norfluoxetine, venlafaxine and the 
combination of both compounds, have significant effects in the embryonic 
development and transcription patterns of genes related with mechanisms of 
detoxification and neurohormonal systems in zebrafish, although each compound 
alone had different response magnitudes.  
Regarding embryo toxicity assays, exposure to different concentrations of 
venlafaxine or norfluoxetine caused low mortality of the embryos, similar to that of the 
control group. The mortality rate increased over time, mainly from 8hpf to 32hpf, 
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raising the question of whether this could be related to increased sensitivity to the test 
drugs due to development of serotonergic and adrenergic systems, which start to form 
at 24hpf in zebrafish embryos (Airhart et al., 2012; Kastenhuber et al., 2010). 
However, increased mortality in this developmental window was also found in the 
control group, within the same range of exposed groups, ruling out this possibility. In 
contrast, exposure to a mixture of norfluoxetine and venlafaxine, caused increased 
mortality in relation to the control, indicating the combined exposure should have 
more severe embryotoxic effects than the single compounds. This mortality increase 
was particularly proeminent at 8hpf, suggesting that the mixture could be acting in 
pathways other then the serotonergic and adrenergic routes, since these are not yet 
developed at this stage. Further investigation is needed in order to clarify this 
possibility. Mortality elicited by the combination of the two substances stabilised 
between 32 and 80hpf. This could be linked to the developmental processes taking 
place in the embryo. Organogenesis occurs during this period (Kimmel et al., 1995), 
with the establishment of systems that could make the embryo more apt to deal with 
harmful compounds to the body.  
The psychotropic drugs investigated caused the appearance of abnormalities in 
exposed embryos, at 80hpf for norfluoxetine and at 32 and 80hpf for venlafaxine and 
32 hpf for the cocktail. The anomalies described were caused by exposure levels in 
the range found in aquatic systems (≥0.64ng/L for norfluoxetine, ≥400ng/L at 32hpf 
and ≥80ng/L at 80hpf for venlafaxine, 3.2+2000ng/L at 32hpf for the cocktail). 
Up-to-date no report is available in the literature describing the presence of embryonic 
anomalies elicited by either norfluoxetine or venlafaxine in fish embryos. In fact, data 
from a previous study suggests that exposure of zebrafish embryos to venlafaxine 
would result in very low frequency of appearance of anomalies (Galus et al., 2013). 
These authors exposed zebrafish embryos to 0, 0.5 and 10μg/L of venlafaxine for 96h. 
The rate of anomalies was approximately 1% in exposed embryos, meaning that was 
a decrease of 3- to 7-fold decrease of anomalies, in 0.5 and 10μg/L concentrations 
respectively. However, results presented herein show significant increase in the 
appearance of anomalies in relation to the control, at 32 and 80hpf, for norfluoxetine 
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(~20%) and venlafaxine (~25%). The differences observed may be due to the use of 
different exposure conditions and/or differences in sensitivity of the test organisms, as 
well as prevalence of anomalies in pigmentation found in this work weren’t analysed 
by the work of Galus and colleagues. Furthermore, in this study, exposure to the 
mixture of 3.2ng/L norfluoxetine and 2000 ng/L venlafaxine, suggests the combined 
substances may initially have stronger effects than exposure to each of the single 
compounds, causing a higher frequency of anomalies. Nevertheless, part of these 
may correspond to developmental delays, with later recovery as suggested by the 
decrease in total anomalies relative to control found at 80hpf. Most has different 
results in the appearance of anomalies. The reduction observed at 80hpf was 
unexpected and seems to point to an antagonistic effect of norfluoxetine and 
venlafaxine, mainly explained by the absence of significant anomalies in the embryos’ 
spine, contrarily to embryos exposed to venlafaxine. Like previously mentioned, 
norfluoxetine and venlafaxine act by selectively inhibiting serotonin 5-HT reuptake 
receptors and adrenergic receptors that on aquatic organisms are present throughout 
most embryonic development (Airhart et al., 2012; Kastenhuber et al., 2010; Kreke 
and Dietrich, 2008). Main anomalies found were in pigmentation, vitelline sac and 
spine. In particular, there was a decrease in pigmentation in embryos, which may be a 
result of the effect of norfluoxetine and venlafaxine on embryo adrenergic receptors, 
which are present in the melanophores stimulating pigmentation (Xu and Xie, 2011). 
This is an indication that both compounds have an effect on adrenergic receptors in 
the zebrafish embryo that should be studied in more detail. There were also 
significant anomalies in the vitelline sac (32hpf) and spine (80hpf). If anomalies in the 
vitelline sac seemed to disappear at 80hpf, minimizing possible effects in populations, 
spinal anomalies in individuals already in a larval stage can influence the population. 
The later can result in decreased swimming performance and, consequently, in major 
difficulty to avoid predators and find food, calling into question the organisms’ survival. 
In the total of anomalies found, higher concentrations of norfluoxetine and venlafaxine 
are the ones that induce greatest effects. It is also important to notice a visible 
significant increase in the appearance of anomalies at concentrations that may be 
75 
 
found in the environment for both tested compounds, indicating that aquatic 
organisms may already been suffering negative impacts of exposure to norfluoxetine 
and venlafaxine.    
Concerning gene expression, a wide range of genes involved in the mode of 
action of the tested pharmaceuticals, and defence mechanisms of zebrafish in 
response to xenobiotics, was tested. mRNA expression of three reference genes was 
also assessed. Recently, the use of a multiple reference gene strategy was suggested 
as the most adequate to normalise mRNA expression (Urbatzka et al., 2013). In the 
present study, among the three reference genes tested, the combinations actb1+rpl8, 
ef1+rpl8 and actb1+rpl8 were found suitable to normalise mRNA expression following 
norfluoxetine, venlafaxine and their cocktail exposure, respectively. Expression of 
these gene combinations was found to be the most stable across treatments in each 
experiment. Normalisation of mRNA expression of the 34 genes investigated by the 
respective combination indicated by NormFinder thus allowed to minimise bias in the 
results obtained (Urbatzka et al., 2013). NormFinder software, based on a 
methodology integrating intra- and intergroup variation of experimental data, proved to 
be helpful and easy of use to find the most stable combinations of reference genes 
across treatments. 
For the genes involved in the mode of action of the drugs tested, significant 
differences among treatments were found for both venlafaxine and norfluoxetine. In 
the single exposure to different concentrations of norfluoxetine, increased expression 
of serotonin receptor 5-ht2c at 80ng/L was found. This was unexpected once that 
norfluoxetine, as SSRI, is expected to act by inhibiting 5-HT receptors (Mennigen et 
al., 2011). However, in humans mainly in the first weeks of exposure, many 
antidepressants can cause over activity of the 5-ht2c receptors, originating some side 
effects in the organism (Milan, 2005); the same could possibly happen in zebrafish 
embryos. Expression of adrenergic receptors, in particular adra2c at the lowest 
concentration tested, tended to be decreased while alterations in embryos’ 
pigmentation were found at the highest test concentrations. These results suggest 
that norfluoxetine interferes with adrenergic receptors. It has been shown previously 
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that these receptors are involved in the pigmentation in zebrafish embryos (Xu and 
Xie, 2011). Embryos exposed to different concentrations of venlafaxine, also showed 
alterations in genes involved in the pharmaceutical mode of action. Venlafaxine acts 
by inhibiting both serotonin and norepinephrine receptor (Gutierrez et al., 2003; 
Mennigen et al., 2011), which means that an inhibition in the transcription of these 
genes would be expected. Serotoninergic genes showed a tendency to inhibition of 
expression, as expected, though at different test concentrations of venlafaxine: 
10000ng/L for serta (-60%) and 5-ht1a (-80%), and 80 and 400ng/L for 5-ht2c (-70 
and 60%, respectively). For adrenergic genes there was an unexpected mixed 
response. Norepinephrine transporter (net) was inhibited in the highest concentration 
of venlafaxine tested. However, adrenergic receptors did not follow the same 
tendency. In fact, adrenergic receptor adra2b showed strong induction of expression 
at concentrations ≥400ng/L, concentrations for which anomalies in embryos’ 
pigmentation were also found. Nevertheless, more investigation is needed in order to 
better understand the relation between modulation of adrenoreceptors and anomalies 
in pigmentation elicited by exposure to either norfluoxetine or venlafaxine. In 
mammals, high concentrations of venlafaxine also affect the dopaminergic system, 
inhibiting the dopaminergic receptors (Sansone and Sansone, 2014).  
In this study, obtained results showed inhibition of the dopamine receptor drd1b (80 
and 400ng/L) in a U-shape response where highest test concentrations elicited 
responses similar to control and lowest venlafaxine level tested. Concomitant 
induction of dat at 400ng/L was additionally found. For the mixture of 3.2ng/L of 
norfluoxetine and 2000ng/L venlafaxine, results revealed inhibition of 5-ht2c but not of 
adra2b. Both low-concentration and non-monotonic responses were previously 
reported to be caused by exposure of non-target organisms to selective serotonin 
reuptake inhibitors (Rodrigues et al., 2014, 2015; Cunha et al., 2016). Moreover, 
according to a recent wide review such responses should be typically expected from 
substances with endocrine-disrupting activity (Vandenberg et al., 2012). The different 
effects may be produced because many receptors, or receptor subtypes, are 
expressed specifically in a single or a few cell types whereas others are found in 
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multiple cell types. Different coregulators (e.g. specific ions) present in the different cell 
types may further contribute to differences in behaviour of target genes. On this regard, 
it is well known that some SSRI and SNRI act on more than one receptor/receptor 
subtype, which may be expressed in different quantities in different cell types and 
organs, therefore producing variable effects on gene expression or cellular 
phenomena. For example, studies have shown that fluoxetine may also interact with 
acetylcholine receptors (Garcia-Colunga et al., 1997) and that eat-6 is a component of 
the pathway that couples 5-HT signaling and acetylcholine neurotransmission in 
Caenorhabditis elegans (Govorunova et al., 2010). eat-6 is expressed in ventral cord 
cholinergic neurons. This gene mediates 5-HT inputs to cholinergic neurons, 
regulating acetylcholine pre-synaptic neurotransmission, and has a post-synaptic role 
at the body wall neuromuscular junctions (Govorunova et al., 2010). According to the 
authors, both stimulatory and inhibitory inputs of serotonergic neurons to cholinergic 
neurotransmission could occur through regulation of different receptor subtypes at 
different cellular targets, resulting in both synergistic or antagonistic effects. Such type 
of cross-regulation could explain divergent response patterns observed in the present 
study. As recently pointed out by Ford and Fong (2016) in an interesting review about 
the effects of these psychotropic drugs, SSRI and SNRI exhibit binding affinity also to 
dopamine reuptake receptors, sigma receptors and enzymes such as nitric oxide 
synthase and a variety of cytochrome P450 enzymes, so that their specificity has been 
debated for years. 
It is also of note that interactions between serotonergic, adrenergic and 
dopaminergic systems (Kreke and Dietrich, 2008) should occur through G 
protein-coupled receptors (GPCRs), which have a variety of physiological roles. 
GPCRs are a large family of protein receptors able to sense extracellular molecules, 
subsequently activating intracellular signal transduction pathways, such as the cyclic 
adenosine monophosphate (cAMP) or the phosphatidylinositol signalling pathways 
(Filmore, 2004; Trzaskowski et al., 2012). GPCRs are activated by a wide variety of 
ligands, including light stimulatory molecules, pheromones, hormones and 
neurotransmitters. Biogenic amines are mainly involved in the regulation of mood and 
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behaviour. Furthermore, not only cross-talking may occur between GPCRs but also 
they may become desensitized when exposed to their ligand for a prolonged period of 
time, either through downregulation of the activated GPCR or through downregulation 
of a different GPCR (Filmore, 2004; Trzaskowski et al., 2012). According to the 
present results, for venlafaxine, alterations observed in 5-ht1a (5-htr1aa) and adra2b 
should act on, inhibitory GPCR, Gi/Go pathway (Kelder et al., 2012; Kutmon et al., 
2016) (Figure 52). 
 
 
Figure 52. Relations between different monoamine receptors and associated G protein-coupled 
receptors (GPCRs) pathways in zebrafish. Gs (stimulatory GPCRs) and Gi (inhibitory GPCRs) use the 
cAMP signal transduction, whereas Gq uses the Phosphatidylinositol signal transduction. Adapted from 
Kelder et al. (2012) and Kutmon et al. (2016). (http://wikipathways.org/index.php/Pathway:WP1389). 
 
   vmat2 and mao interact with monoamines like serotonin, norepinephrine and 
dopamine. vmat2 is responsible for the intracellular transport of these monoamines, 
while mao is responsible for their oxidative deamination (Wimalasena, 2010; Sallinen 
et al., 2009). Both venlafaxine and norfluoxetine cause increase in the levels of 
serotonin and norepinephrine in the synaptic cleft (Kreke and Dietrich, 2008; Fent et 
al., 2006) and because of that, mao is expected to reduce its activity in the presence 
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of these compounds. In fact, in the highest concentration of venlafaxine tested 
(10000ng/L) inhibition of mao expression was observed, suggesting that only 
concentrations above 2000 to 10000ng/L of venlafaxine would be able to cause 
intracellular monoamine depletion at a level high enough to downregulate mao activity. 
For vmat2, decreased expression inhibition was observed at 80 and 400ng/L 
venlafaxine and in embryos exposed to the mixture of 3.2ng/L of norfluoxetine and 
2000ng/L of venlafaxine. In fact, inhibition of monoamine reuptake is expected to 
reshape presynaptic and postsynaptic responses causing long-term depletion of 
vesicular stores (Kristensen et al., 2011). Such a mechanism could cause a decrease 
in both mao and vmat2. Indeed, in rats there are indications that SSRIs have an 
inhibitory effect in vmat2 (Yasumoto et al., 2009). Also inhibition of vmat2 can 
contribute to an increase in extracellular levels of catecholamines, like serotonin and 
norepinephrine (Wimalasena, 2011). The mode of action of venlafaxine is precisely 
associated with increased levels of these catecholamines in the synaptic cleft, which 
supports a possible inhibition of vmat2. Obtained results therefore suggest that an 
inhibitory effect of antidepressants in vmat2 may also occur in fish species, but more 
work is needed, to confirm this hypothesis. 
   Nuclear receptors are involved in the regulation of different phases of xenobiotics 
metabolisation (Xu et al., 2005). For all different nuclear receptors tested, embryos 
exposed to norfluoxetine showed significant differences only in the expression of 
rarga that was strongly increased at 3.2ng/L. Nuclear receptors like rarga are 
responsible for the regulation of genes involved in xenobiotic metabolism. It is thus 
possible that norfluoxetine stimulates this receptor at 3.2ng/L, but more tests are 
needed to support this. In embryos exposed to different concentrations of venlafaxine 
wider alterations in nuclear receptors were visible, namely inhibition of rxrab, rxrga 
and rxrgb expression (400ng/L). rxr nuclear receptors can form heterodimers with 
other nuclear receptors, regulating their main targets (Xu et al, 2005). Thanks to that 
binding ability, rxr are involved in the regulation of a high amount of drug metabolising 
enzymes (Xu et al., 2005). This means that the decreased expression found in some 
rxr forms can compromise the regulation of drug metabolising enzymes which can 
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influence negatively the organisms’ homeostasis. In another study, it was found that 
rxrg signalling can influence dopamine receptor d2 in mice (Krzyzosiak et al., 2010). 
In this study, drd2b showed no decreased gene expression. However, expression of 
drd1b was found to be lower than control at same concentration found for rxrg 
(400ng/L), suggesting zebrafish rxrg expression may influence dopamine receptor d1. 
All ppar nuclear receptors showed decreased expression at 400ng/L of venlafaxine 
and some even in the range 80-2000ng/L. Previous studies in fish, demonstrated that 
ppar are involved in lipid and xenobiotic metabolism (Maradonna et al., 2015; Wang et 
al., 2008). Thereby, the observed alterations suggest that zebrafish capacity to 
metabolise lipids and xenobiotics is compromised in the presence of venlafaxine even 
at environmentally relevant concentrations. In addition to their primary action as lipid 
sensors and regulators of lipid metabolism, ppar are also expressed in the brain where 
they have anti-inflammatory and neuroprotective roles in the central nervous system. 
ppar-α loss of function, for example, has been shown to promote repetitive behavior 
and cognitive inflexibility (D’Agostino et al., 2015). Moreover, another important issue 
that has been raised is the role of pparα and pparγ agonists in drug addiction and 
dopaminergic neurons. ppar agonists showed an important role in reducing self-intake 
of drugs in mammals, as well as reduced stimulation of dopaminergic neurons 
involved in mesolimbic dopamine pathway of the brain reward system (Panlilio et al., 
2012; Melis et al., 2008). Activation of pparα and pparγ was shown to suppress 
sensitization that develops the effects of psychotropic drugs when they are 
administered chronically; these effects could be reversed by ppar antagonists that had 
no effect on drug uptake on their own. Because behavioral sensitization is thought to 
contribute to the development of drug dependence, this came to support interest of 
ppar agonists as treatments for drug dependence (Mascia et al., 2012; Foll et al., 
2013). The underexpression of ppar elicited by venlafaxine exposure in the present 
study, could suggest the occurrence of drug dependence. It may also explain the 
induction of dat at 400ng/L. However, more research is needed to better understand 
this question, even because lack of physiological dependence in humans is one the 
advantages in the use of venlafaxine (Kelsey, 2000). ppar genes expression was also 
81 
 
tested in the cocktail assay, but no alterations were found in exposed larvae, meaning 
that the mixture did not change significantly the action of this nuclear receptor. Given 
that no change in ppar expression was obtained in the presence of norfluoxetine, the 
results further indicate an antagonistic effect of the two psychotropic drugs on these 
nuclear receptors. 
   Members of the superfamily ABC in aquatic species are part of the mechanism 
denominated MXR (multixenobiotic resistance) (Kurelec, 1992) and are considered 
the first line of defence against toxic substances and its metabolites at the cellular 
level (Bard, 2000). For ABC transporters tested, embryos exposed to norfluoxetine 
showed diminished expression of abcb4 (0.64ng/L) and activation of abcc1 (3.2ng/L). 
In embryos exposed to venlafaxine there was decreased expression of abcb4 
(2000ng/L), abcc1 (400ng/L) and abcg2a (80 and 400ng/L). The abcb4 gene encodes 
the functional P-glycoprotein in zebrafish, playing the role of first line of defence 
against toxic substances in the organism, incorporating the phase 0 of 
biotransformation (Fischer et al., 2013). The role this gene plays in the organism is 
critical as it provides great protection to fish against toxic compounds. Expression of 
this gene, therefore, should not exhibit large variation in order to not compromise 
individuals’ survival (Epel et al., 2008). Thereby decreased abcb4 caused by 
norfluoxetine or venlafaxine can be life-threatening to embryos living under high 
chemical stress conditions. abcc1 and abcg2a are responsible for the efflux of 
metabolites outside the cell (phase III of biotransformation) (Xu et al., 2005). This 
suggests that low concentrations of norfluoxetine may result in abcc1 stimulation to 
efflux norfluoxetine or its metabolites out of the cell to defend the organism against 
their potential damage. In contrast, low concentrations of venlafaxine appears to 
impair cells’ ability to efflux metabolites; aquatic organisms may thus lose efflux 
capacity of potentially harmful compounds for cell function, suffering injury to the 
homeostasis of the organism. It is also important to refer that the decreased 
expression of ABC transporters reported herein occurred at concentrations levels 
found in the aquatic environment. Therefore, populations of aquatic fish may be 
already suffering these effects, and their consequences, in systems where one or the 
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other of these psychotropic drugs have been detected. Expression of ABC 
transporters abcc1, abcg2 and abcc2 was also tested in the cocktail assay but no 
significant alterations were found, indicating the mixture does not affect the action of 
these transporters. The expression levels obtained for the mixture had intermediate 
values in relation to the exposure to venlafaxine and norfluoxetine alone, again 
pointing out an antagonistic relationship between the compounds, in this case for the 
action of ABC transporters. 
For norfluoxetine, no differences in gene expression could be found for the 
biotransformation enzymes tested: cyp1a1, cyp3a65 and gstπ. In some part, this is 
not unexpected once that nuclear receptors pxr and ahr2, which regulate the 
expression of cyp3a and cyp1a, respectively (Lehman et al., 1998; van der Oost, 
2003), did not show relevant differences in their expression in the presence of the 
tested drugs. For venlafaxine there was visible inhibition of cyp3a65 at 10000ng/L, 
though pxr and ahr2 were not affected. 
An interesting characteristic of cyp enzymes is that a drug can be metabolised by 
one enzyme and inhibited by that same enzyme (Lynch and Price, 2007). In humans 
CYP2D6 has a major role in the metabolisation of norfluoxetine and venlafaxine (Ring 
et al., 2001; Margolis et al., 2000; Shams et al., 2006). Nevertheless, norfluoxetine is 
also able to inhibit the action of this enzyme (Lynch and Price, 2007). The same is 
true for fluoxetine. Under these circumstances CYP2C19, CYP2C9, CYP3A4 and 
CYP3A5 become more relevant for fluoxetine metabolism especially during chronic 
administration of the drug, when metabolisation by CYP2D6 is limited through the 
parent SSRI and its major metabolite (Lynch and Price, 2007). On the other hand, 
CYP2D6 is conserved in chimpanzee, Rhesus monkey, rat, chicken, and frog (Pan et 
al., 2016). However, in the National Centre for Biotechnology Information (NCBI) 
CYP2D6 has 8 homologs in 5 species, but none of them is a fish species (Pan et al., 
2016). In Ensembl 84, it has 97 orthologs from 49 species of chordates, none of them 
is a fish species either, suggesting that in zebrafish CYP2D6 role could be fulfilled by 
different cyp enzymes. Of interest is also the gap occurring between dosing and drug 
decrease due to cyp activation. While inhibition of cyp enzymes is very rapid, their 
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induction usually takes more time to occur. For some drugs (e.g. phenobarbital) there 
can be a delay up to one week between the beginning of dosing and the decrease in 
concentration of the drug due to cyp activation (Lynch and Price, 2007).  
A panoply of possibilities may therefore be advanced for the results obtained in 
this investigation, including that for norfluoxetine the test concentrations may be 
below the threshold for cyp activation, the time window analysed is still within the gap 
phase of cyp increase or that these drugs are metabolised by other cyp enzymes. 
Worthy to mention is that 80hpf larvae exposed to fluoxetine, under similar conditions, 
exhibited inhibition of cyp1a1, cyp3a65 and gstπ expression, as well as of sod, though 
at comparatively higher test concentrations (Cunha et al., 2016). In addition, pxr was 
increased compared to the control and ahr2 showed a biphasic response 
characterised by activation of expression in the lower exposure levels and diminished 
expression in the higher fluoxetine treatments. 
HCA, with heat maps, and PCA were subsequently carried out with the results 
obtained for gene expression in order to better understand associations between 
genes and the effects of the different concentrations tested for each compound. For 
norfluoxetine the HCA separated larvae exposed to 3.2ng/L from those exposed to the 
remaining tested concentrations, probably due to the higher degree of induction found 
in that concentration. The heat map helps to understand the general panorama of 
gene expression obtained. Indeed, this showed a general tendency for induction in 
gene expression, although in most cases with values close to those of control and 
only sporadic differences detected. The PCA does not support such distinction, 
indicating that there were no differences between the tested concentrations and the 
control. This was expected once that, as already mentioned, no relevant alterations 
were detected for the majority of genes and no particular pattern of expression could 
be noted for any test concentration. 
One interesting result comes from the comparison between norfluoxetine and the 
parental compound (fluoxetine). Hiemke and Hartter (2000), work indicates that 
norfluoxetine is more potent than parental compound to inhibit neurotransmitter 
uptake. However, results obtained in this work do not support this. In fact, the present 
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study indicates for the first time that influence of norfluoxetine over development of a 
teleost embryo appears to be, notably, less severe than that of fluoxetine. Comparing 
the results of this investigation with the ones obtained in a recent study (Cunha et al., 
2016), norfluoxetine showed comparatively lower mortality and gross damage to the 
organism than fluoxetine. In the present work the highest concentration of 
norfluoxetine tested (0.0014μM) is similar to the lowest concentration of fluoxetine 
tested in Cunha, et al (2016) (0.0015μM). Comparing these two concentrations, it can 
be observed the rate of anomalies caused by fluoxetine exposure was well above the 
one caused by norfluoxetine in embryonic development of zebrafish at 32hpf. Table 3 
summarises gene expression alterations obtained after exposure of zebrafish 
embryos for 80hpf to similar concentrations of fluoxetine, norfluoxetine, venlafanixe 
and the cocktail. At the molecular level, more significant differences in the expression 
of genes involved in the detoxification mechanism were visible for fluoxetine than for 
norfluoxetine at similar concentrations. 
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Table 3. Summary of the gene expression changes observed in zebrafish embryos exposed to relevant 
concentrations of fluoxetine, norfluoxetine, venlafaxine and cocktail. The symbols denote significant 
induction (↑), inhibition (↓) or no alteration (~) relative to the respective control group. 
Gene Fluoxetine Cocktail
512ng/L (0.0015μM) 3.2ng/L 400ng/L 80ng/L 400ng/L 2000ng/L
serta ↓** ~ ~ ~ ~ ~ §
5-ht2c ↓** ~ ~ ↓ ↓ ~ ↓
5-ht1a ~** ~ ~ ~ ~ ~ §
dat ↓** ~ ~ ~ ↑ ~ §
drd1b ~** ~ ~ ↓ ↓ ~ ↓
drd2b ↓** ~ ~ ~ ~ ~ §
net ~** ~ ~ ~ ~ ~ §
adra2a ~** ~ ~ ~ ~ ~ §
adra2b ~** ~ ~ ~ ↑ ↑ ~
adra2c ↓** ~ ~ ~ ~ ~ §
vmat2 ↓** ~ ~ ↓ ↓ ~ ↓
mao ~** ~ ~ ~ ~ ~ §
pxr ↑* ~ ~ ~ ~ ~ §
ahr2 ~* ~ ~ ~ ~ ~ §
raraa ~* ~ ~ ~ ~ ~ §
rarab ~* ~ ~ ~ ~ ~ §
rarga ↓* ↑ ~ ~ ~ ~ §
rxraa ↓* ~ ~ ~ ~ ~ §
rxrab ~* ~ ~ ~ ↓ ~ §
rxrbb ~* ~ ~ ~ ~ ~ §
rxrga ↑* ~ ~ ~ ↓ ~ §
rxrgb ~* ~ ~ ~ ↓ ~ §
pparα ↓* ~ ~ ~ ↓ ~ ~
pparβ ↓* ~ ~ ↓ ↓ ~ ~
pparγ ↓* ~ ~ ↓ ↓ ↓ ~
abcb4 ~* ~ ~ ~ ~ ↓ §
abcc2 ↓* ~ ~ ~ ~ ~ ~
abcc1 ~* ↑ ~ ~ ↓ ~ ~
abcg2a ↓* ~ ~ ↓ ↓ ~ ~
cyp1a1 ~* ~ ~ ~ ~ ~ §
cyp3a65 ~* ~ ~ ~ ~ ~ §
gstπ ~* ~ ~ ~ ~ ~ §
sod ~* ~ ↓ ~ ~ ~ §
cat ↑* ~ ~ ~ ~ ~ §
Norfluoxetine Venlafaxine
 
§ - not determined; * (Cunha et al., 2016); ** (Cunha et al., unpublished) 
 
For venlafaxine more intense alterations were observable, resulting in differences 
in the tested concentrations in relation to control. Heat map projection showed a 
general tendency to inhibition in the genes’ transcription. The inhibition was higher in 
the range 80 to 2000ng/L; these concentrations were grouped by HCA against the 
remaining treatments, supporting the results showing a tendency for a U-shaped 
response. Based on the PCA, embryos exposed to 80, 40 and 10000ng/L of 
venlafaxine show differences in relation to the control. Moreover, it is evident that 
400ng/L venlafaxine is the concentration with an unique expression response (mainly 
inhibition of rxr and ppar nuclear receptors, and abc transporters, as well as induction 
of dopamine and adrenergic receptors), most distant from that of the control. In the 
following concentrations recuperation to near control values appears to start occurring. 
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The differences in expression were mild, however, fairly comparable to those obtained 
previously for fluoxetine (Cunha et al., 2016). The set of genes selected for 
investigation of the cocktail effects, is promising as biomarker of exposure to 
venlafaxine during embryonic development. The non-linear dose-response observed 
poses challenges to common risk assessment approaches, in what concerns risk 
calculation. Risk estimation based on conventional toxicological parameters (e.g. No 
Observed Effect Concentration, NOEC, or low Effect Concentrations, EC) cannot be 
easily applied here, similar to previous observations for other substances with 
endocrine disrupting activity (Vandenburg et al., 2012). 
PCA showed curious correlations patterns among some genes altered by venlafaxine 
exposure. ppar receptors, abc transporters, drd1b, 5-ht2c and vmat2 were well 
correlated to each other, in a positive manner. The correlation between ppar receptors 
and abc transporters may indicate that venlafaxine acts in the lipidic metabolism of 
zebrafish embryos. Like previously mentioned, in fish, ppar receptors are involved in 
lipid sensing and metabolism (Maradonna et al., 2015; Wang et al., 2008), while abc 
transporters are known for their efflux capacity of cholesterol in mammals, mainly 
abca1 and abcg1 (Phillips, 2014). Also, human patients treated with venlafaxine show 
significant alterations of cholesterol levels in the serum (Allgulander et al., 2004; 
Simon et al., 2004; Hummels et al., 2011). Venlafaxine thus appears to interfere with 
cholesterol levels, also in fish by affecting the expression of abc transporters and ppar 
receptors. Figure 53 shows the known lipid metabolism pathway in zebrafish. Here it 
is possible to see the action of ppar receptors and a myriad of abc transporters. 
Several lipid ligands for some of these nuclear receptors, and their regulated genes 
are shown, including ppar receptors for fatty acids. These receptors act by forming 
heterodimers with retinoid X receptors (RXR). Upon binding to various ligands, three 
classes of proteins are synthesised including lipid binding proteins, the ATP-binding 
cassette (ABC) transporters and cytochrome P450 member proteins which catalyze 
lipid anabolism, metabolism and elimination. In addition to lipid metabolism, some 
members of the cytochrome P450 family genes are responsible for activation of 
procarcinogens, detoxification of environmental toxins and metabolism of drugs and 
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xenobiotics (Lynch and Price, 2007). Here abcc2 is associated to the lipid metabolism, 
namely with steroids resulting from cholesterol metabolism. Alterations of abcb4 
expression are also associated with the lipid metabolism, specifically with fatty acids, 
through regulation by pparα. In order to understand if other abc transporters are 
activated by this metabolism in the presence of venlafaxine, further evaluation of 
those target genes would be needed. 
 
Figure 53. Nuclear receptors in lipid metabolism and toxicity of zebrafish. PPAR, peroxisome 
proliferator-activated receptor; RXR, retinoid X receptors; RAR, retinoic acid receptors; VDR, vitamin D 
receptor; NR1, nuclear hormone receptor subfamily 1; ABC, ATP-binding cassette transporters; cyp, 
cytochrome P450 gene family. Adapted from: Kelder et al. (2012) and Kutmon et al. (2016) 
(http://wikipathways.org/index.php/Pathway:WP1326). 
 
The results also showed that major alterations in the gene expression of zebrafish 
larvae exposed to venlafaxine occurred at low environmentally relevant 
concentrations, rather than at high test concentrations of this psychotropic drug. This 
is an aspect that has been reported in the literature (Fong and Ford, 2014) and is 
further supported by the results of the present work.  
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For the cocktail assays, HCA, showed higher similarity of its expression profile to 
norfluoxetine than venlafaxine. Nevertheless, the combination of both compounds 
resulted in a response pattern different from those of the single drugs. abc 
transporters and ppar receptors showed intermediate expression levels between 
norfluoxetine and venlafaxine whereas neurohormonal genes showed higher 
downregulation degree, compared to single compounds. PCA showed the clear 
separation between the neurohormonal genes tested from nuclear receptors and 
detoxification transporters. Overall, data suggests an antagonistic effect between the 
two psychotropic drugs. Surprisingly, a very low rate of norfluoxetine to venlafaxine 
(with differences over 2 orders of magnitude between the two compounds) was found 
to produce milder effects than venlafaxine. This was particularly evident in the number 
of spinal anomalies and some target genes, mainly the ones involved in both drugs 
metabolism. Taken together they suggest that a small concentration of norfluoxetine 
would be enough to reverse detrimental effects elicited by venlafaxine. Moreover, 
considering this, it is possible that the environmental impact of venlafaxine over 
teleost embryos may be attenuated in aquatic ecosystems where the two drugs 
co-occur. Although there are some cases, like the anomalies in embryos pigmentation 
at 32hpf, where synergetic effects are found. According to the rates of mortality and 
abnormalities obtained, and the changes highlighted in Table 3 the toxicity of the 
compounds can be ranked as follows, from highest to lowest: 
fluoxetine>venlafaxine>cocktail~norfluoxetine.   
In conclusion, the present work contributed to increase the knowledge base on effects 
of low concentrations of psychotropic drugs on non-target aquatic organisms, by 
evaluating sensitive endpoints in a developmental model for which alterations found 
may reflect at the population level. The data provided comes to support the need for 
alternate approaches to the risk assessment of substances with endocrine disrupting 
activity. It also points out the importance of developing routine biomonitoring of 
contamination of aquatic systems by these compounds. The research performed 
provided an expression profile, based on a set of affected genes, of potential interest 
to be employed as biomarker of exposure to venlafaxine and mixtures of norfluoxetine 
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and venlafaxine. Finally, it calls the attention for the need to better assess effects of 
exposure to drug metabolites in non-target species and of combinations of chemicals 
that may co-occur in the aquatic environment. 
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Chapter 5: Conclusions and future 
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5. Conclusions and future perspectives 
 
With this study, it was concluded that the presence of norfluoxetine, venlafaxine 
and the combination of both substances in the aquatic environment have effects on 
zebrafish embryos, in particular embryonic development, gene expression of 
serotonergic, dopaminergic and adrenergic systems as well as in the gene expression 
involved in detoxification mechanisms. 
In the presence of different concentrations of norfluoxetine and venlafaxine 
mortality was not affected. The same did not happen for the cocktail exposure, where 
significant mortality was observed. Exposure to single compounds or to the cocktail 
resulted in increased rate of gross anomalies during embryonic development, mainly 
at the highest concentrations tested. The anomalies found most often were alteration 
in pigmentation and vitelline sac at 32hpf, and pigmentation and spinal anomalies at 
80hpf in the case of venlafaxine.  
Concerning gene expression of neurohormonal and metabolisation mechanisms, 
different responses were visible, according to the compound(s) to which embryos 
were exposed. For norfluoxetine there was a tendency for a slight induction of gene 
expression and a small number of genes presented significant alterations in relation to 
control. There were no remarkable correlations among genes; main patterns 
observed associated nuclear receptors known to dimerise to exert their action, such 
as ppar, rxr and rar. No differences among norfluoxetine concentrations were found in 
relation to the control. The results also, appear to counteract the idea that 
norfluoxetine is more potent than the parental compound although test concentrations 
were low. For venlafaxine general inhibition of gene expression was visible and a 
wider range of genes was affected, compared to norfluoxetine. Inhibition was higher in 
the 400ng/L concentration, that is environmentally relevant. Visible correlations were 
noted between ppar’s, abc transporters, vmat2, drd1b and 5-ht2c, suggesting that 
venlafaxine can interfere with lipid metabolism and the activity of dopamine neurons 
linked to brain reward systems. Alterations in adra2b and 5-ht2c suggested a 
disturbance in the Gi/Go pathway. The general dose-response pattern obtained for 
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venlafaxine showed a U-shape, where 80, 400 and 2000ng/L were the most affected; 
an apparently typical response for these drugs. Differences found in adrenergic 
receptors can explain anomalies in the pigmentation of embryos and larvae. In 
addition, abcb4 expression was also significantly inhibited at environmentally relevant 
concentrations, meaning that populations may already be at risk. The pool of genes 
tested for the cocktail exposure showed different responses for neurohormonal 
receptors and genes responsible for metabolisation. Neurohormonal receptors were 
highly inhibited, while metabolisation genes presented an intermediate response in 
relation to exposure to single compounds.  
In conclusion, aquatic organisms may suffer adverse effects due to the presence 
of norfluoxetine and venlafaxine in ecosystems. However, future developments in this 
area are needed for better understanding the effects of these compounds on aquatic 
organisms. It would be important to address possible effects of exposure during the 
embryonic phase in swimming behaviour and the reproductive level, as well as 
establish behavioral tests to assess preference or avoidance for contaminated 
medium. Deeper studies about the mechanisms that can be affected by exposure to 
these compounds, specially lipid metabolism, dopaminergic neurons activity and 
Gi/Go pathway in the case of venlafaxine. It would also be important extend the pool 
of genes tested for the cocktail, in order to better understand the potential antagonistic 
effects between the two drugs and their implications to aquatic organisms. 
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APPENDIX A1 
Genbank accession numbers, primer sequences and concentrations, amplicon lengths and 
efficiency of reaction for the target genes investigated in this study. 
Primers Sequence
Final 
Conc.
(5’→3’) (nM)
F: TACTGATGATGCTTGGCTTAATC
R: TCTCTGGAAAGGTGAAGTTAGG 
F: GCTCGAGCTCTCCTCAGAAA
R:TCGGATGGTGGACTGTATCA
F: GCACAGCATCAAGGGAAACA
R: CCTCATCCACTGAAGAACCGA
F: AAGGGTATCGAGGACCGTCT
R: AATCCTGACCCTGAACGATG
F: AACTCTTCGCAGGTGCTCAT
R: ACAAACTGCCATTGGAGACC
F: TGACCTGCTGAACCCTCTCT
R: AAGGGCGAAATCCATCTTCT
F: TCTGGACTCTTTCCCGTCTCTCAA
R: ATTCACTGTTGCCGTTGCCGT
F: GTCGTCTGGCTTGTGGAGTG
R: TGTCAGCGGGCTAGTGCTT
F: CAGGAGCGTTTGGCTACTTC
R: ATCGGTGTCGTCTTTCCAAC
F: CTTTTTCAGACGTGCGATGA
R:TTGGCACTGTCTTCTGTTGC
F:ATTCAATGGCATCTCCTG
R:GCGGCTTAATATCCTCTG
F:CGCCGCATCAAATCACATAAAC
R:TGAATGGGTTGGACAGTATTTAGC
F:TCACAACTTGGGCGTGGAGGC
R:CGCATCTTGCAGACCAGCTCAG
F:ATCTCAGTTCTTCGTTGCAGGTAG
R:CGTTGATGATGGATGGGTGATGG
F:CGCGGAATGGATACTCACG
R:GCTGATGACGGACGGATGAC
F:GTAGTGGAGTGTGGATGTGAA
R:GTGCTGATGTCTGATGGATGA
F:ATGGATTACTACCACCAGAAC
R:TCTCCACAGAGTGATTCGAGC
F:CCCGCCAACTGTACGATGTCA
R:GGGTCCAGTCCAGCATAGAAA
F:CATCTTGCCTTGCAGACATT
R:CACGCTCACTTTTCATTTCAC
pxr
pparα
NM_001161
333.1
600 81 88.3
rarab
NM_131399.
1
300 115 109.4
rarga
NM_131339.
1
300 79 117.6
rxrgb
NM_001002
345.1
300 114 97.7
raraa
NM_131406.
2
300 118 108.7
rxrbb
NM_131238.
1
300 105 100.7
rxrga
NM_131217.
2
300 105 99.6
rxraa
NM_001161
551.1
600 99 101.8
rxrab
NM_131153.
1
300 87 109.4
cat
NM_130912.
1
300 91 113
DQ069792.1 300 94 112.7
gstπ NM_131734 300 105 119
Cu/Zn 
sod
Y12236 300 113 110
cyp1a1
NM_131879.
1
300 97 102
cyp3a65
NM_001037
438.1
300 82 91
abcc2 NM_200589 300 87 116.5
abcg2a
NM_001042
775.1
300 97 113.1
abcb4 JQ014001 300 159 110.6
abcc1
XM_0026611
99
300 99 125.1
Gene
Accession 
number
Amplicon 
length (bp)
Efficiency 
(%)
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Genbank accession numbers, primer sequences and concentrations, amplicon lengths and 
efficiency of reaction for the target genes investigated in this study. 
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